<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006112.pub2" GROUP_ID="CF" ID="652105062111024801" MERGED_FROM="" MODIFIED="2013-10-30 12:57:29 +0000" MODIFIED_BY="Nikki Jahnke" REVIEW_NO="0074" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2013-10-30 12:57:29 +0000" MODIFIED_BY="Nikki Jahnke">
<TITLE>Inspiratory muscle training for cystic fibrosis</TITLE>
<CONTACT MODIFIED="2013-10-30 12:57:29 +0000" MODIFIED_BY="Nikki Jahnke"><PERSON ID="657D7CB682E26AA200433359AF5CE512" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Brian</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Houston</LAST_NAME><SUFFIX>MCSP</SUFFIX><POSITION>Senior Lecturer in Physiotherapy</POSITION><EMAIL_1>brian.houston@tees.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Health &amp; Social Care</DEPARTMENT><ORGANISATION>Teesside University</ORGANISATION><ADDRESS_1>Victoria Road</ADDRESS_1><CITY>Middlesbrough</CITY><ZIP>TS1 3BA</ZIP><REGION>Cleveland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1642 384978</PHONE_1><FAX_1>+44 1642 384105</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-10-30 12:57:29 +0000" MODIFIED_BY="Nikki Jahnke"><PERSON ID="657D7CB682E26AA200433359AF5CE512" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Brian</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Houston</LAST_NAME><SUFFIX>MCSP</SUFFIX><POSITION>Senior Lecturer in Physiotherapy</POSITION><EMAIL_1>brian.houston@tees.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Health &amp; Social Care</DEPARTMENT><ORGANISATION>Teesside University</ORGANISATION><ADDRESS_1>Victoria Road</ADDRESS_1><CITY>Middlesbrough</CITY><ZIP>TS1 3BA</ZIP><REGION>Cleveland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1642 384978</PHONE_1><FAX_1>+44 1642 384105</FAX_1></ADDRESS></PERSON><PERSON ID="37D51F2782E26AA201071537D86D6DBF" ROLE="AUTHOR"><FIRST_NAME>Nicola</FIRST_NAME><LAST_NAME>Mills</LAST_NAME><POSITION>Physiotherapist</POSITION><EMAIL_1>nicola.mills@uhl-tr.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Physiotherapy Department</DEPARTMENT><ORGANISATION>Glenfield Hospital</ORGANISATION><ADDRESS_1>Groby Road</ADDRESS_1><CITY>Leicester</CITY><ZIP>LE39QP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 116 2871471</PHONE_1></ADDRESS></PERSON><PERSON ID="11636" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><LAST_NAME>Solis-Moya</LAST_NAME><EMAIL_1>artusol@gmail.com</EMAIL_1><EMAIL_2>arturosolismoya@me.com</EMAIL_2><ADDRESS><DEPARTMENT>Servicio de Neumología</DEPARTMENT><ORGANISATION>Hospital Nacional de Niños</ORGANISATION><ADDRESS_1>Caja Costarricense del Seguro Social</ADDRESS_1><ADDRESS_2>PO Box 220 - 1017</ADDRESS_2><CITY>San José</CITY><COUNTRY CODE="CR">Costa Rica</COUNTRY><PHONE_1>+ 506 2255 1838</PHONE_1><FAX_1>+506 2223 9316</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-10-10 11:59:22 +0100" MODIFIED_BY="Tracey Remmington">
<UP_TO_DATE>
<DATE DAY="10" MONTH="10" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="7" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="10" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2013-10-10 11:58:59 +0100" MODIFIED_BY="Brian W Houston">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-10-10 11:58:54 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="10" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis &amp; Genetic Disorders Group's Cystic Fibrosis Register identified two references to a single study that was potentially eligible for inclusion in the review; this study has been excluded (<LINK REF="STD-Irons-2012" TYPE="STUDY">Irons 2012</LINK>). Searches of MEDLINE, CIHNAL, AMED and SCOPUS identified two additional studies that were potentially eligible for inclusion in the review, but both of these were also excluded (<LINK REF="STD-Santana_x002d_Sosa-2013" TYPE="STUDY">Santana-Sosa 2013</LINK>; <LINK REF="STD-Vivodtzev-2013" TYPE="STUDY">Vivodtzev 2013</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-10-10 11:58:59 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="10" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>No new studies have been included in this update of the review and our conclusions have remained the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-07-09 13:15:04 +0100" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-07-09 13:15:04 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="28" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis Trials Register identified three new references which were potentially eligible for inclusion in this review (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Howard-2000" TYPE="STUDY">Howard 2000</LINK>). Two studies were eligible for inclusion (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>); the third study was excluded (<LINK REF="STD-Howard-2000" TYPE="STUDY">Howard 2000</LINK>).</P>
<P>Additional searching undertaken for the updated review identified one study that was potentially eligible for inclusion (<LINK REF="STD-Sartori-2008" TYPE="STUDY">Sartori 2008</LINK>); however this was excluded on closer examination.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-15 15:48:27 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="28" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Teesside, Middlesbrough</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-10-30 11:14:23 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-07-09 13:27:43 +0100" MODIFIED_BY="[Empty name]">
<TITLE>The training of muscles that cause the chest to expand in order to take air into the lungs for people with cystic fibrosis</TITLE>
<SUMMARY_BODY MODIFIED="2013-07-09 13:27:43 +0100" MODIFIED_BY="[Empty name]">
<P>Cystic fibrosis is the most common life-limiting genetic condition in Caucasians. The life-expectancy of newly diagnosed patients is increasing. Inspiratory muscle training may improve quality of life, lung function and exercise tolerance in people with cystic fibrosis, so that these are closer to the levels found in people who do not have cystic fibrosis. It may also boost the clearance of mucus. Inspiratory muscle training can be performed without the help of a carer and wherever the individual feels appropriate. We searched for randomised or quasi-randomised controlled clinical trials to determine the effects of inspiratory muscle training in the treatment of people with cystic fibrosis. We included eight studies with 180 participants in the review, but we could not combine results from these studies to answer our questions, because the studies either did not publish enough details or did not use the same standard measurements. Given this, we cannot recommend the use, or not, of this intervention. We do recommend that future studies make more use of health-related quality of life and exercise tolerance measures. We also suggest there should be agreement upon standard measurements used.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-09-23 13:30:16 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-05-13 14:18:55 +0100" MODIFIED_BY="[Empty name]">
<P>Cystic fibrosis is the most common life-limiting genetic condition in Caucasians and the life-expectancy of those newly diagnosed is increasing. Inspiratory muscle training may be a way of improving the lung function and quality of life of people with cystic fibrosis. Hence there is a need to establish whether this intervention is beneficial.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effect of inspiratory muscle training on health-related quality of life, pulmonary function and exercise tolerance.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-07-09 13:20:25 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials register comprising of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.</P>
<P>Date of most recent search: 08 July 2013.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-05-15 13:10:44 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised or quasi-randomised clinical controlled trials comparing different inspiratory muscle training regimens with each other or a control in people with cystic fibrosis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Three review authors independently applied the inclusion and exclusion criteria to publications and assessed the quality of the included studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-09-23 13:30:16 +0100" MODIFIED_BY="[Empty name]">
<P>Fourteen studies were identified. Of these eight studies with 180 participants met the review inclusion criteria. There was wide variation in the quality of the included studies. Data were not published in sufficient detail or with sufficiently similar outcome measures in these studies to perform meta-analyses.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-05-13 15:06:04 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We have not found any evidence to suggest that this treatment is either beneficial or not. We would advise that practitioners evaluate on a case-by-case basis whether or not to employ this therapy. We recommend that future studies make more use of health-related quality of life and exercise tolerance measures; and that there is an agreement upon a single standard measure of classifying the clinical status of the participants.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-10-30 11:14:23 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-10-30 11:10:04 +0000" MODIFIED_BY="Nikki Jahnke">
<CONDITION MODIFIED="2008-05-15 13:23:17 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Cystic fibrosis (CF) is the result of a genetic mutation that directly affects ion transport within cells by altering the function of the cystic fibrosis transmembrane conductance regulator (CFTR). In the case of secretory cells, this results in the production of dehydrated, viscous and ultimately dysfunctional secretions (<LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>). Two main sites of secretory cells are the digestive and respiratory systems. Both of these systems have a major influence on health and development. The adverse effect on the respiratory system in people with CF contributes to it being the most common, life-limiting autosomal recessive genetic disorder in Caucasians (<LINK REF="REF-Kosorok-1996" TYPE="REFERENCE">Kosorok 1996</LINK>); and in the UK it currently affects over 7500 people (<LINK REF="REF-CF-Trust-2005" TYPE="REFERENCE">CF Trust 2005</LINK>). With advancement in the medical management of the condition, the life-expectancy of babies newly diagnosed is now into their fifties (<LINK REF="REF-Dodge-2007" TYPE="REFERENCE">Dodge 2007</LINK>). This brings with it a responsibility for all clinicians working with people with CF, and in particular physiotherapists, to consider ways of enhancing quality of life.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-10-10 12:01:46 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Inspiratory muscle training (IMT) involves the training of muscles that act to expand the chest in order to take in air into the lungs. The specific loads applied to the inspiratory muscles for the purpose of training are flow, threshold or resistive in nature (<I>see </I>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for explanations of these terms: threshold load, resistive loading). Training regimens vary in terms of intensity and duration of session or programme or both (<LINK REF="REF-McConnell-2002" TYPE="REFERENCE">McConnell 2002</LINK>). It is possible to develop a training regimen that combines a method of stressing the inspiratory muscles with a specific training approach, e.g. continuous or interval training (<I>see</I> <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Patients can perform IMT independently and wherever they feel it appropriate. While the initial provider and setting for initiating IMT will usually involve a therapist in a clinical setting, generally the user of IMT will be left to implement their own training, with or without supervision from another person, such as a carer.</P>
</INTERVENTION>
<THEORY MODIFIED="2008-05-15 13:28:32 +0100" MODIFIED_BY="Nikki Jahnke">
<P>A Cochrane Systematic Review has found some limited evidence that general conditioning exercise (physical training) can improve the function of the lungs, the exercise tolerance and health-related quality of life of people who have CF closer to that of healthy people (<LINK REF="REF-Bradley-2008" TYPE="REFERENCE">Bradley 2008</LINK>). More specifically, IMT may also have these benefits (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>). In addition, it has been suggested that IMT may also enhance the clearance of mucus, which is fundamental to management of the condition (<LINK REF="REF-Chatham-2004" TYPE="REFERENCE">Chatham 2004</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-10-30 11:10:04 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Prior to previous versions of this review (<LINK REF="REF-Houston-2008" TYPE="REFERENCE">Houston 2008</LINK>; <LINK REF="REF-Houston-2009" TYPE="REFERENCE">Houston 2009</LINK>), there was no systematic review of the currently available evidence from randomised controlled trials (RCTs) or quasi-randomised controlled trials as to whether IMT is beneficial, nor on the optimal IMT programme (i.e. the nature of the training load and specifics of the training protocol), for people with CF. This review has now been updated. </P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-05-01 14:11:15 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>To determine the effects of IMT in the management of people with CF. Specifically, we plan to examine the effects of IMT in people with CF on:</LI>
<OL>
<LI>health-related quality of life;</LI>
<LI>pulmonary function;</LI>
<LI>exercise tolerance;</LI>
</OL>
<LI>To report any adverse effects reported in the included trials.</LI>
<LI>To compare the effects of IMT performed using resistive devices, threshold-loading devices and isocapnic hyperpnoea (<I>see</I> <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) on the above outcomes and adherence.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2013-10-30 11:10:52 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-10-14 12:17:36 +0100" MODIFIED_BY="Nikki Jahnke">
<CRIT_STUDIES>
<P>Randomised or quasi-randomised clinical controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with CF, of any age, diagnosed by clinical criteria, sweat test or genotyping or both.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-10-14 12:17:36 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Inspiratory muscle training (as achieved by voluntary isocapnic hyperpnoea, resistive loading or threshold loading: <I>see</I> <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) compared with each other or with no or sham IMT (device or procedure that appears to be IMT but does not have its training properties).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-04-28 11:27:40 +0100" MODIFIED_BY="Nikki Jahnke">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-04-28 10:22:45 +0100" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Health-related quality of life</LI>
<LI>Pulmonary function tests (performed at rest):</LI>
<OL>
<LI>forced expiratory volume at one second (FEV<SUB>1</SUB>)</LI>
<LI>forced vital capacity (FVC)</LI>
</OL>
<LI>Exercise tolerance:</LI>
<OL>
<LI>field-based tests</LI>
<LI>laboratory-based tests</LI>
</OL>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-05-15 13:31:34 +0100" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Pulmonary function tests (performed at rest):</LI>
<OL>
<LI>maximal inspiratory pressure (PI<SUB>max</SUB>)</LI>
<LI>inspiratory capacity (IC)</LI>
</OL>
<LI>Respiratory muscle function (strength and endurance)</LI>
<LI>Frequency and duration of respiratory infections, hospitalisations</LI>
<LI>Adherence to the IMT regimen</LI>
<LI>Death or survival</LI>
<LI>Adverse effects (pneumothorax, musculoskeletal pains or injuries, others)</LI>
<LI>Costs</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-10-30 11:10:52 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-10-30 11:10:52 +0000" MODIFIED_BY="[Empty name]">
<P>We identified relevant studies from the Group's Cystic Fibrosis Trials Register using the term 'inspiratory muscle training'.<BR/>
<BR/>The Group's Cystic Fibrosis Trials Register, which is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <I>The Cochrane Library</I>), quarterly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals - <I>Pediatric Pulmonology</I> and the <I>Journal of Cystic Fibrosis</I>. Unpublished work is identified by searching the abstract books of four major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference, the North American Cystic Fibrosis Conference and the Australia and New Zealand Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html">Cystic Fibrosis and Genetic Disorders Group Module</A>. Date of the last search of the Group's Cystic Fibrosis Trials Register: 08 July 2013.</P>
<P>We also performed separate searches of the following databases: MEDLINE, Embase, CINAHL, AMED (Allied and Complementary Medicine), PEDro (<A HREF="http://www.pedro.fhs.usyd.edu.au/index.html">The Physiotherapy Evidence Database</A>), BIOSIS Previews, Science Direct and SCOPUS to 2013, using both the Cochrane RCT and Cystic Fibrosis search filters; and terms specific to the intervention (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). We also searched <A HREF="http://www.controlled-trials.com">Current Controlled Trials</A> and the <A HREF="http://www.update-software.com/national/">UK National Research Register </A>for ongoing and recently completed studies. These searches were updated and run again on the 01 August 2013 (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-08-30 14:35:12 +0100" MODIFIED_BY="[Empty name]">
<P>For the original review, we also contacted manufacturers and study investigators and checked reference lists of relevant literature.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-08-30 14:37:58 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY_SELECTION MODIFIED="2008-04-28 10:48:24 +0100" MODIFIED_BY="Nikki Jahnke">
<P>All three authors screened the output of electronic searches (title and abstract) to identify potentially eligible studies. From the full reports, all three authors independently selected studies for inclusion into the review. We planned to resolve any disagreements by discussion and if necessary by arbitration from a third person (Helen Handoll); however, this was not necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-10-13 15:10:23 +0100" MODIFIED_BY="Nikki Jahnke">
<P>All three authors independently collected data using standardised forms made available by the Cystic Fibrosis and Genetic Disorders Group. The authors did not need to resolve any disagreements. </P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-08-30 14:37:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>In order to assess the risk of bias, using a standardised form, all three authors independently assessed study quality according to the following criteria from the Cochrane risk of bias tool (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>): sequence generation; allocation concealment; the degree of blinding; whether incomplete data was included in the analysis (i.e. the intention-to-treat principle); whether there was selective reporting of results and any other identified sources of bias. We also commented on aspects of external validity, in particular the description of study participants and study interventions (e.g. in resistive IMT, has inspiratory flow rate been specifically controlled or not?), and the reliability of outcome assessment (including any reporting of the participants' 'familiarity' with the intended method of assessment), especially length of follow up. We reported on whether the included studies used systematic methods to record adverse events. We planned to resolve any disagreements by discussion and if necessary by arbitration from a third person (Helen Handoll); however, this was not necessary.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-10-13 15:18:06 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We have graphically presented quantitative data for the outcomes listed in the inclusion criteria. For each study, we planned to calculate risk ratios (RR) and 95% confidence intervals (CIs) for dichotomous outcomes, and mean differences (MD) and 95% CIs for continuous outcomes.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2008-08-13 15:58:22 +0100" MODIFIED_BY="Tracey Remmington">
<P>Ideally when conducting a meta-analysis combining results from cross-over studies, we will use the inverse variance methods that are recommended by Elbourne (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). However, if there are limited data available we planned to either use first arm data only or treat the cross-over trial as if it was a parallel trial (assuming a correlation of zero as the most conservative estimate). Elbourne says that this approach produces conservative results as it does not take into account within-patient correlation (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). Also each participant appears in both the treatment and control group, so the two groups are not independent. There was one cross-over trial included in the review. Currently we have reported results from this trial narratively but for the first update of this review we plan to analyse this using the generic inverse variance (GIV) method. At which point, if we need to combine data from cross-over studies in a meta-analysis with data from parallel studies, we will use the methods discussed by Curtin (<LINK REF="REF-Curtin-2002a" TYPE="REFERENCE">Curtin 2002a</LINK>; <LINK REF="REF-Curtin-2002b" TYPE="REFERENCE">Curtin 2002b</LINK>; <LINK REF="REF-Curtin-2002c" TYPE="REFERENCE">Curtin 2002c</LINK>).</P>
<P>Where studies measured data longitudinally, the authors based the analysis on the final time point results. Methods are not yet available to carry out a meta-analysis of aggregate longitudinal data, where individual patient data (IPD) is not available.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-05-11 15:28:21 +0100" MODIFIED_BY="Brian W Houston">
<P>We contacted the authors of some of the studies in order to obtain more specific data to that presented; e.g. means and standard deviations; however, we have received no response to date.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-08-30 14:37:14 +0100" MODIFIED_BY="Nikki Jahnke">
<P>If sufficient studies (at least four) had been included which we were able to combine in a meta-analysis, we planned to test for heterogeneity between comparable studies using a standard chi² test and to consider this statistically significant at P &lt; 0.1. In addition we planned to use the value of the I<I>²</I>
<SUP> </SUP>statistic to assist in determining levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We planned to base our judgements on the convention that 0 to 40% is unlikely to be important, 30 to 60% could be indicative of moderate heterogeneity, 50 to 90% may indicate important levels of heterogeneity and 75 to 100% suggests considerable heterogeneity (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-04-28 10:52:12 +0100" MODIFIED_BY="Nikki Jahnke">
<P>If sufficient data were available, we planned to attempt to assess publication bias by preparing a funnel plot.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-04-28 10:49:51 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We planned to pool the results of comparable groups of studies using the fixed-effect model and calculate 95% CIs.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-05-15 13:37:04 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We would not perform meta-analysis if we considered it would be misleading to quote an average value for the treatment effect, such as where there is substantial and statistically significant heterogeneity. As pooling of data from the included studies is inappropriate or not possible due variations in the level of IMT employed, we have provided appropriate narrative descriptions of the results. However, we have included graphical representation of some of the extracted data, which may be added to in the future (<I>see</I> <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>).</P>
<P>Should there have been significant heterogeneity and if there had been a sufficient number of included studies, we would have explored the possible causes of the heterogeneity using subgroup analysis in terms of the following parameters:</P>
<OL>
<LI>type of IMT (e.g. low level versus high level);</LI>
<LI>regimen of IMT (e.g. daily versus three times per week);</LI>
<LI>characteristics of study participants</LI>
<OL>
<LI>age (up to 16 years versus older than 16 years);</LI>
<LI>gender of study participants;</LI>
<LI>genotype;</LI>
<LI>participants with 'weak' inspiratory muscles strength compared to those with preserved strength (as determined by PI<SUB>max</SUB>);</LI>
<LI>participants with mild hyperinflation to those with severe hyperinflation (as determined by their total lung capacity (TLC)) or mixed populations with comparable interventions.</LI>
</OL>
<LI>definition of outcome measures.</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-05-13 15:05:23 +0100" MODIFIED_BY="Nikki Jahnke">
<P>If sufficient studies had been included, we planned to perform sensitivity analyses exploring the effects of published and unpublished studies, allocation concealment, assessor blinding and loss to follow up. We planned to conduct best-case and worst-case scenario plots to investigate the potential effects of loss to follow up.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-10-30 11:14:23 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-10-30 11:14:23 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-10-30 11:12:09 +0000" MODIFIED_BY="[Empty name]">
<P>The results of the first stage of the search are given below.</P>
<UL>
<LI>The Cystic Fibrosis and Genetic Disorders Group's CF Trials Register provided 15 citations for 10 studies all of which were considered as potentially eligible for inclusion.</LI>
<LI>A search of EBSCOhost databases (OVID for the original review), MEDLINE, Embase, CINAHL, BIOSIS Previews and AMED (Allied and Complementary Medicine) returned 188 potential studies, of which, 14 were considered as eligible for potential inclusion.</LI>
<LI>A search of PEDro (<A HREF="http://www.pedro.fhs.usyd.edu.au/index.html">The Physiotherapy Evidence Database</A>) returned 73 potential studies, of which, 12 were considered for potential inclusion.</LI>
<LI>A search of Science Direct and SCOPUS did not produce any studies not already identified by the above searches.</LI>
</UL>
<P>All three authors reviewed the abstracts of the returned studies and selected those relevant to the scope of this review. This process left us with a final pool of 14 studies. From these 14, eight studies with a total of 180 participants were included (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>) and six were excluded (<LINK REF="STD-Howard-2000" TYPE="STUDY">Howard 2000</LINK>; <LINK REF="STD-Irons-2012" TYPE="STUDY">Irons 2012</LINK>
; 
<LINK REF="STD-Keens-1977" TYPE="STUDY">Keens 1977</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2013" TYPE="STUDY">Santana-Sosa 2013</LINK>
; 
<LINK REF="STD-Sartori-2008" TYPE="STUDY">Sartori 2008</LINK>
; 
<LINK REF="STD-Vivodtzev-2013" TYPE="STUDY">Vivodtzev 2013</LINK>). Of the eight included studies, four were published as abstracts only (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-10-30 11:14:23 +0000" MODIFIED_BY="[Empty name]">
<P>A full comparison of the included studies can be found in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial design</HEADING>
<P>Of the eight included studies, seven were of a parallel design; i.e. a control and an experimental group participating in the study concurrently (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>) with one of these having three arms to the study, i.e. a control and two levels of training (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>). One was of a cross-over design; i.e. the participants were randomly allocated to receive the training first or second (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>); we appreciate that these data would best be analysed in RevMan using the generic inverse variance (GIV) method; however, the trial authors did not supply the parameters required for this analysis.</P>
<P>The duration of the intervention ranged from four (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>) to 12 weeks (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>) and all outcomes were recorded at the end of the trial period in each case.</P>
<P>The studies were run in a number of different countries: the USA (<LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>); the UK (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>); the Netherlands (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>); Canada (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>); Russia (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>); and Austria (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>). While most were single centre studies (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>), it was unclear in three studies if they were single or multicentre (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>).</P>
<P>All studies were relatively small with the number of participants ranging from 11 (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>) to 29 (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Participant characteristics were not consistently reported across studies. Two studies did not give any indication of the exact mean age or age range of participants, but indicated that they were adults (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>). One further study explicitly stated that participants were adults and gave a mean age of 22.5 years (<LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>). Two studies reported age ranges that included children, adolescents and young adults; 6 to 18 years (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>) and 9 to 24 years (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>). The remaining three studies gave more detailed information on patient age and indeed split according to treatment group (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>). In each study ages were similar between groups, but while the mean age for participants in two groups was in the early 20s (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>), in one study it indicated that participants were children and adolescents (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>).</P>
<P>Six of the studies did not report on the gender split in participants (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>). Two studies reported on gender split by treatment group; in one study there were equal numbers of males and females (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>) and in the second there were slightly more males than females (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>There was great variation as to the method and level of training employed by the included studies; e.g. IMT as a percentage of maximum effort or by threshold loading. Three studies used 80% compared to 20% of maximal effort (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>); one study used 60% of maximal effort (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>); one study used 40% of maximal effort (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>); one study used 30% of maximal effort (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>) and two studies did not specify the level of resistance (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>). The frequency of training also varied. In two studies the frequency and duration of training was unclear (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>). Three studies used similar training regimens (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>); of these one recommended a duration for each session of 10 to 15 minutes twice daily (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>), of 15 minutes twice daily (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>) and 30 minutes in total daily (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>). The remaining two studies used a regimen of training three times per week, but the duration of the sessions either varied (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>) or was not stated (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The outcome measures selected by the studies also varied greatly. All studies reported some measure of inspiratory or respiratory muscle strength. Most studies reported at least one measure of lung function; the most common of these were FEV<SUB>1</SUB> (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>) and FVC (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>). Two studies used the Chronic Respiratory Disease Questionnaire to report QoL (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>), but other studies also reported on similar outcomes such as perceived breathlessness (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>) and fatigue (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-10-10 12:03:21 +0100" MODIFIED_BY="Nikki Jahnke">
<P>One study was excluded from the original search as the allocation was not randomised (<LINK REF="STD-Keens-1977" TYPE="STUDY">Keens 1977</LINK>); likewise a study identified in the 2011 update was excluded as the allocation was not randomised (observational study) (<LINK REF="STD-Sartori-2008" TYPE="STUDY">Sartori 2008</LINK>). A further study was identified and excluded from the 2011 update as the intervention was not appropriate (<LINK REF="STD-Howard-2000" TYPE="STUDY">Howard 2000</LINK>); likewise two studies identified in the 2013 update were excluded as the interventions were not appropriate (<LINK REF="STD-Irons-2012" TYPE="STUDY">Irons 2012</LINK>; <LINK REF="STD-Vivodtzev-2013" TYPE="STUDY">Vivodtzev 2013</LINK>). Although a form of IMT was used as an intervention in the remaining study, it was used in combination with another exercise based intervention; therefore, it was impossible to attribute any observed changes to IMT alone. As such, the study was excluded (<LINK REF="STD-Santana_x002d_Sosa-2013" TYPE="STUDY">Santana-Sosa 2013</LINK>) (<I>see</I> <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-09-28 12:31:38 +0100" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2011-09-19 13:28:53 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Generation of allocation sequence</HEADING>
<P>Although eight of the studies state that they randomised their participants to the treatment groups, only one study offers any indication of the methods of allocation by stating that they employed the minimisation method (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>). We graded this study as having a low risk of bias, but the remaining seven studies were graded as having an unclear risk of bias. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Concealment of allocation sequence</HEADING>
<P>None of the included studies made specific reference as to how, or even whether, this was addressed. All studies were assessed as having an unclear risk of bias in relation to this criteria.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2011-09-20 15:12:14 +0100" MODIFIED_BY="Nikki Jahnke">
<SUBSECTION>
<HEADING LEVEL="4">Performance bias</HEADING>
<P>We have scored all the included studies as having a high risk of bias in this parameter. In all studies there was clear difference between the experimental and control training; ranging from no details being provided for the control group (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>) and "no IMT training" (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>) through to minimal training and "sham" training (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>). Although we acknowledge the methodological difficulties of blinding the participants to this type of intervention, it would have been straight forward to survey the participants at the end of data collection to establish whether they could tell if they received the training dose or not.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dectection bias</HEADING>
<P>Two studies blinded the outcome assessors at the final data collection session, although they did not state whether this was the case at the initial assessment or even if the same assessors carried out all the assessments (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>). Another study reports that the observers were blinded, although it does not expand on the level of this (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>). The other five studies make no overt reference to any blinding (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>).</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-09-19 13:36:21 +0100" MODIFIED_BY="[Empty name]">
<P>No study explicitly refers to intention-to-treat. However, five studies do report withdrawals. In the de Jong study, one participant in the intervention group withdrew after experiencing earache at 40% PI<SUB>max</SUB> training intensity (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>). In the Asher study, two participants did not perform one of the post-treatment outcome measures, namely PI<SUB>Max</SUB>, due to expiration up to residual volume resulting in coughing (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>). In the Sawyer study two participants did not complete their pulmonary function tests: one was due to an oversight on the part of the researchers; and the other did not complete the test (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>). There is no indication as to which group these participants are from (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>). We consider that, for all three studies, these withdrawals relate to the true outcome and therefore introduce a high risk of bias.</P>
<P>In the Chatham study, three participants in the control group did not complete the trial (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>); and in the Amelina study, one participant in the intervention group did not complete the trial (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>). Neither of these last two studies offered any explanation for these withdrawals. As they are both abstracts we have graded them as 'unclear' on the grounds that they had limited space in which to explain the omissions. The two trials added during the update to this review did not provide statistical data on their control groups, merely stating that there was no change in their outcomes (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>). We do acknowledge, however, that these were both abstracts published in conference proceedings and that there are likely to be editorial constraints responsible for this. Therefore, they are regarded as having an 'unclear' risk of bias.</P>
<P>The remaining three trials do not provide any information with regards to participant withdrawals, so we judge these to have an unclear risk of bias (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-09-28 12:06:04 +0100" MODIFIED_BY="[Empty name]">
<P>One study mentions that the investigators carried out post-training measures of pulmonary function but do not report the results (<LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>). It is acknowledged that this study is only published as an abstract; however, there is a potential risk of bias due to the limited reporting of their outcomes. Likewise for the study by Amelina, two outcomes (respiratory muscle strength and dyspnoea) are mentioned as having been analysed, but no data are provided for them (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>).</P>
<P>There was insufficient information provided by the other publications to make a judgement on the risk of bias due to selective reporting from six trials and we judge these to have an unclear risk of bias (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-09-28 12:31:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We have given all the included studies a grading of 'unclear' risk of bias as none provided sufficient information to arrive at a definitive conclusion.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-09-28 12:38:57 +0100" MODIFIED_BY="[Empty name]">
<P>Due to the lack of studies using identical intensities of IMT or outcome measures, or both, it continues to be impossible, at this time, to pool any of the data; we have deemed it inappropriate to combine the data from the included trials. Please note that all outcomes were recorded at the end of the study period in each study.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Health-related quality of life</HEADING>
<P>Two of the studies included in the review reported having used an outcome measure of this type. Both used the Chronic Respiratory Disease Questionnaire (CRDQ), which evaluates four domains considered important to individuals with chronic airflow obstruction; dyspnoea, mastery, fatigue and emotion (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">i. 80% of maximal effort</HEADING>
<P>One study reported significant improvement in the two parameters of mastery and emotion (P &lt; 0.01) (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>). No statistically significant change was reported in the other paper for any of the four categories (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">ii. 60% of maximal effort</HEADING>
<P>The Sawyer study did not report on this outcome (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iii. 40% of maximal effort</HEADING>
<P>The de Jong study did not report on this outcome (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iv. 20% of maximal effort</HEADING>
<P>No statistically significant change was reported in the paper for any of these four categories (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">v. unspecified level of maximal effort</HEADING>
<P>The Asher and Albinni studies did not report on this outcome (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Pulmonary function tests (performed at rest)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. Forced expiratory volume at one second (FEV<SUB>1</SUB>)</HEADING>
<P>Data for FEV<SUB>1</SUB> were reported in six of the included studies (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>). One study stated that post-training measures of pulmonary function were determined, but did not report any further details (<LINK REF="STD-Heward-2000" TYPE="STUDY">Heward 2000</LINK>); and the remaining study did not mention this outcome (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">i. 80% of maximal effort</HEADING>
<P>Enright reported mean and SD data for all groups and reported no significant difference between all three of their groups (two intensities of IMT (see also 20% of maximal effort below) and a control) (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">ii. 60% of maximal effort</HEADING>
<P>The Sawyer study presented FEV<SUB>1</SUB> in litres and reported a P value indicating no difference between IMT and control (P = 0.10) (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iii. 40% of maximal effort</HEADING>
<P>The de Jong study presents FEV<SUB>1</SUB> in litres and reports a P value indicating no difference between IMT and control (P = 0.82) (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>).</P>
<P>
<I>iv. 30% of maximal effort</I>
</P>
<P>The Amelina study presented FEV<SUB>1</SUB> in per cent predicted and reports a mean improvement within the training group from 48% to 51% with a P value of 0.014 (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>).</P>
<P>
<I>v. 20% </I>of maximal effort</P>
<P>Enright reported mean and SD data for this group, but did not report any significant difference between IMT and control (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">vi. unspecified level of maximal effort</HEADING>
<P>The Asher and Albinni studies did not report any data, but state that there was no change in FEV<SUB>1</SUB> in either the IMT or the control group (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. Forced vital capacity (FVC)</HEADING>
<P>This outcome is reported in three studies (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>); all using the same unit of measurement (litres).</P>
<SUBSECTION>
<HEADING LEVEL="6">i. 80% of maximal effort</HEADING>
<P>Enright presented mean and standard deviations for all groups, pre- and post-IMT and these figures have been presented in the graphs. There were no reported statistically significant changes following the training (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>). Chatham did not report on this outcome (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">ii. 60% of maximal effort</HEADING>
<P>This outcome was not reported by Sawyer (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iii. 40% of maximal effort</HEADING>
<P>The de Jong study quoted mean and standard deviations for all groups, pre- and post-IMT and these figures have been presented in the graphs. There were no reported statistically significant changes following the training, but de Jong did report the actual level of significance (P<I> </I>= 0.99) (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>).</P>
<P>
<I>iv. 30% of maximal effort</I>
</P>
<P>The Amelina study presented FVC in per cent predicted and reports a mean improvement within the training group from 65% to 68% with a P value of 0.049 (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">v. 20% of maximal effort</HEADING>
<P>Enright presented mean and standard deviations for all groups, pre- and post-IMT and these figures have been presented in the graphs. There were no reported statistically significant changes following the training (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">vi. unspecified level of maximal effort</HEADING>
<P>Albini stated there was no change in FVC in either group, but gave no further details (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>). This outcome was not reported by Asher (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Exercise tolerance</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. Field-based tests</HEADING>
<P>No studies reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. Laboratory-based tests</HEADING>
<P>Three studies reported VO<SUB>2</SUB>max (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">i. 80% of maximal effort</HEADING>
<P>Neither study reported on this outcome (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">ii. 60% of maximal effort</HEADING>
<P>This outcome was not reported by Sawyer (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iii. 40% of maximal effort</HEADING>
<P>The de Jong study reported no statistically significant change in VO<SUB>2</SUB> max (P = 0.99) (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iv. 20% of maximal effort</HEADING>
<P>Enright did not report this outcome (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">v. unspecified level of maximal effort</HEADING>
<P>One study reported a significant improvement in VO<SUB>2</SUB>max within the IMT group (P = 0.01) (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>); although no data were reported to allow inclusion in our analysis. A second study reported pre- and post-intervention mean scores but no statistical analysis, although they did state that no difference was detected between the groups (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>).</P>
<P>One study reported on "exercise capacity" although no units were provided not was there any explanation as to the method of assessment; they reported no improvement in this outcome (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Pulmonary function tests (performed at rest)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. Maximal inspiratory pressure (PI<SUB>max</SUB>)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">i. 80% of maximal effort</HEADING>
<P>Neither study reported on this outcome (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">ii. 60% of maximal effort</HEADING>
<P>When the data for this outcome from the Sawyer study are entered into the analysis there is a significant difference in favour of the treatment group, MD 26.00 (95% CI 8.63 to 43.47) (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iii. 40% of maximal effort</HEADING>
<P>The de Jong study did not report on this outcome (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>).</P>
<P>
<I>iv. 30% of maximal effort</I>
</P>
<P>The Amelina study presented PI<SUB>max</SUB> in per cent predicted and reports a mean improvement within the training group from 77% to 91% with a P value of 0.023 (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">v. 20% of maximal effort</HEADING>
<P>The Enright study did not report on this outcome (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">vi. unspecified level of maximal effort</HEADING>
<P>Asher utilised two inspiratory measures (Pim-FRC and PI<SUB>max</SUB>) suggesting that one measurement technique was used but at two different lung volumes (<LINK REF="STD-Asher-1983" TYPE="STUDY">Asher 1983</LINK>). The study reported significant changes in both measures in the IMT group (P &lt; 0.025 and P &lt; 0.05 respectively). The investigators also reported that, for the Pim-FRC measure, only three participants registered an increase that was more than two standard deviations (2SD) from the control group; and for the PI<SUB>max</SUB> measure, two participants had an increase greater than two SD from the control values.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. Inspiratory capacity (IC)</HEADING>
<P>This outcome was not reported by any study.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Respiratory muscle function (strength and endurance)</HEADING>
<P>Inspiratory muscle endurance (IME) was reported in two studies (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">i. 80% of maximal effort</HEADING>
<P>The Chatham study reported figures for mean (SD) and a P value for the training group only; therefore, they have not been included in our analysis. There was a mean improvement within the training group from 118 (31.5) to 149 (24.7) mmH<SUB>2</SUB>O with a P value of less than 0.04 (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>). Enright did not report this outcome (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">ii. 60% of maximal effort</HEADING>
<P>This outcome was not reported by Sawyer (<LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iii. 40% of maximal effort</HEADING>
<P>The de Jong study quoted figures for mean, standard deviation and P value and has therefore been included in our analysis. There was a statistically significant difference in favour of the IMT group, MD 12.00 (95% CI 0.55 to 23.45) (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
<P>
<I>iv. 30% of maximal effort</I>
</P>
<P>The Amelina study reported this outcome in joules (J) and reports a mean improvement within the training group from 89J to 150J with a P value of 0.002 (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">v. 20% of maximal effort</HEADING>
<P>Enright did not report this outcome (<LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">vi. unspecified level of maximal effort</HEADING>
<P>Albinni reported that IME improved significantly in the training group (P<I> = </I>0.0002) (<LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Frequency and duration of respiratory infections, hospitalisations</HEADING>
<P>This outcome was not reported by any study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Adherence to the IMT regimen</HEADING>
<P>This outcome was not reported by any study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Death or survival</HEADING>
<P>No deaths were reported and survival was not analysed in any study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Adverse effects (pneumothorax, musculoskeletal pains or injuries, others)</HEADING>
<P>One study, using 40% of maximal effort, reported that one participant experienced earache whilst performing IMT (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Costs</HEADING>
<P>This outcome was not reported by any study.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-08-30 15:36:07 +0100" MODIFIED_BY="[Empty name]">
<P>Overall the quality of the included studies was inconsistent and none addressed all aspects completely. The execution of the included studies (randomisation and blinding) ranged from being fully acknowledged, considered and reported to either being merely stated as "randomised to the two groups" or not being mentioned. The external validity (with particular regard to the participant demographics) was explicit in only three of the studies (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>). This aspect is of particular significance given that people who have CF are the target population. The nature of the disease means that two people of similar age, height and weight may have been affected by the condition in drastically different ways and therefore may not "match" as far as clinical status goes. Adverse events were poorly covered by the studies, with only one making specific reference to this (<LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>). Two studies report withdrawals but offer no explanation for these (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>). We acknowledge that the nature of the intervention (IMT) makes it very difficult to blind the participants to which arm they are in, although five studies made use of "sham" interventions for controls (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-de-Jong-2001" TYPE="STUDY">de Jong 2001</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>; <LINK REF="STD-Sawyer-1993" TYPE="STUDY">Sawyer 1993</LINK>).</P>
<P>There is currently insufficient evidence to either support or refute the use of IMT for people with CF (<LINK REF="REF-Altman-1995" TYPE="REFERENCE">Altman 1995</LINK>). There are several factors that may have contributed to this conclusion. Firstly, four out of the eight studies have only been published as abstracts within conference proceedings. This format limits the amount of detailed data that are presented and, therefore, that can be extracted from the studies. This is particularly true in this case. Without that detail a full meta-analysis cannot be performed and this subsequently detracts from the rigour of the process. Another, more generic, factor relates to the execution of studies examining the effects of a rehabilitation technique for people with CF. A systematic review requires homogeneity between the included studies to allow firm conclusions to be drawn. Despite only finding eight studies which met the inclusion criteria of this review, the variation in their methodologies and outcomes (type and units) was such that no combined analyses could be made. These differences occurred in all the major aspects of the studies, i.e. the outcomes employed, the selected units of measurement for certain of these outcomes and the method and extent to which the clinical status of the participants was established or reported.</P>
<P>Two pulmonary function measures, FEV<SUB>1</SUB> and FVC, are both routinely used in general clinical practice to monitor the pulmonary function and (due to the nature of the condition) the disease severity within people with CF. It could be argued that expiratory measures such as these would not be altered by an inspiratory intervention. We, however, support the studies' use of expiratory measures, primarily, because of their routine clinical usage and relevance in monitoring the progression of the disease. In selecting task specific measures some studies are opting for ones that specifically assess changes within the muscles of ventilation, e.g. diaphragm thickness. The problem with this is that they are not measures with which people with CF, or even the average professional working in the field, would be sufficiently familiar in order to be able to draw any meaningful conclusions. It would appear, even from this small sample, that this dilemma continues and needs resolving. Descriptive analysis of the studies considered suggests that the measures that can best detect the effects of an IMT programme are PI<SUB>max</SUB> exercise tests such as inspiratory muscle endurance and, to a lesser extent, VO<SUB>2</SUB>max. Although it is acknowledged that this is not supported by a meta-analysis of trials, they are the measures the included studies report as showing significant improvement within their IMT groups. Also, these are measures that are of particular relevance to professionals involved in the rehabilitation of people with CF and ones that are most likely to influence quality of life.</P>
<P>Only two of the studies included in the review reported having used an outcome measure assessing health-related quality of life (<LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Enright-2004" TYPE="STUDY">Enright 2004</LINK>). We believe that this is a major omission on the part of the other studies, which severely limits the external validity of the research base. There is an ever growing drive to consider the efficacy of our interventions, as McClarey and Duff summarise, in the UK it is being driven centrally from the UK National Health Service (UK NHS) (<LINK REF="REF-McClarey-1997" TYPE="REFERENCE">McClarey 1997</LINK>). What McClarey and Duff fail to fully acknowledge is that efficacy cannot be fully established without thorough assessment of how people with a particular condition perceive the benefits of their treatment (<LINK REF="REF-McClarey-1997" TYPE="REFERENCE">McClarey 1997</LINK>). This ought to be of particular importance in long-term life-limiting conditions, such as CF. It is acknowledged, however, that certain of the studies may have been undertaken at a time before this became such an important consideration within clinical practice.</P>
<P>Due to the life-limiting nature of CF, the clinical status of the participants recruited to studies in this population is of particular importance. The participants from the included studies have a mean age of approximately 18.5 years. With average life expectancy around 31 years (<LINK REF="REF-CF-Trust-2007" TYPE="REFERENCE">CF Trust 2007</LINK>), the participants in these studies are effectively in middle age. It is possible that due to the progressive nature of the condition, the pulmonary function of the participants prevented the benefits shown in healthy populations manifesting in this participant group (<LINK REF="REF-Enright-2000" TYPE="REFERENCE">Enright 2000</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE MODIFIED="2008-05-11 17:36:57 +0100" MODIFIED_BY="Brian W Houston">
<P>Given that we have not found any evidence to suggest that this treatment is either beneficial or not. We would advise that practitioners evaluate on a case-by-case basis whether or not to employ this therapy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-05-11 17:39:14 +0100" MODIFIED_BY="Brian W Houston">
<P>We recommend that future studies choose task specific measures such as PI<SUB>max</SUB> and inspiratory muscle strength and endurance as well as exercise tests such as VO<SUB>2</SUB>max. Such functional measures ought to dovetail nicely with an assessment of health-related quality of life.</P>
<P>To facilitate such future research and to improve research into the remedial benefits of IMT, it is necessary for the research community to agree upon a single standard measure of classifying the clinical status of the participants.</P>
<P>Finally, there is emerging evidence to suggest that IMT is beneficial to people with other chronic respiratory conditions, such as COPD (<LINK REF="REF-O_x0027_Brien-2008" TYPE="REFERENCE">O'Brien 2008</LINK>). It would be prudent to apply this to the clinical population and implement longitudinal studies to assess the role of IMT in maintaining good pulmonary function and exercise tolerance within the CF population.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-04-28 12:00:47 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We acknowledge the valuable contribution to the protocol stage of this review from Professor Cees van der Schans before he stepped down from the review team.</P>
<P>We thank the following for their help and advice at both the protocol and review stage: Mark Elkins, Helen Handoll, Kylie Hill, Nikki Jahnke, Ashley Jones, Heather McIntosh, Vicki Whittaker, Dr Gerard Ryan (editor) and Dr Harold Soloff (consumer referee).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-04-28 12:01:02 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Brian Houston drafted the protocol with comments from Helen Handoll and Cees van der Schans.</P>
<P>Nicola Mills, Arturo Solis-Moya and Brian Houston extracted data and assessed trial quality. Brian Houston drafted the full review with comments from Nicola Mills and Arturo Solis-Moya.</P>
<P>Brian Houston acts as guarantor of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-09-20 15:18:32 +0100" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Update 2011</B>
<BR/>Due to Teesside University (location of the lead author) changing its search engine, some of the search strategies have been re-written. The search strategies in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> have superseded those in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-10-30 11:22:18 +0000" MODIFIED_BY="Brian W Houston">
<STUDIES MODIFIED="2013-10-30 11:22:18 +0000" MODIFIED_BY="Brian W Houston">
<INCLUDED_STUDIES MODIFIED="2013-09-23 13:59:10 +0100" MODIFIED_BY="Brian W Houston">
<STUDY DATA_SOURCE="PUB" ID="STD-Albinni-2004" MODIFIED="2013-09-23 13:41:57 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Albinni 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-23 13:41:31 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Albinni S, Rath R, Renner S, Eichler I</AU>
<TI>Additional inspiratory muscle training intensifies the beneficial effects of cycle ergonometer training in patients with cystic fibrosis [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>Suppl1</NO>
<PG>S63</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:41:31 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:41:31 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE148a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-23 13:41:57 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eichler I, Renner S, Albinni S, Nachbaur E, Rath R</AU>
<TI>Inspiratory muscle training adds beneficial effects to cycle ergometer training in patients with cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>Suppl 28</NO>
<PG>320</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:41:57 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:41:57 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE148b"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amelina-2006" MODIFIED="2013-09-23 13:43:07 +0100" MODIFIED_BY="[Empty name]" NAME="Amelina 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-23 13:43:07 +0100" MODIFIED_BY="Brian W Houston" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Amelina E, Cherniak A, Chikina S, Krasovsky S, Appaeva A</AU>
<TI>Inspiratory muscle training (IMT) in cystic fibrosis adults [abstract]</TI>
<SO>European Respiratory Society Annual Congress</SO>
<YR>2006</YR>
<VL>Sep 2-6; Munich, Germany</VL>
<PG>716s, Abstract no: P4112</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:43:05 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:43:05 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE177"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asher-1983" MODIFIED="2013-09-23 13:48:12 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Asher 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-09-23 13:45:07 +0100" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;PH131a&lt;/p&gt;" NOTES_MODIFIED="2013-09-23 13:45:07 +0100" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Asher MI, Pardy RL, Coates AL, Thomas E, Macklem PT</AU>
<TI>The effects of inspiratory muscle training in patients with cystic fibrosis</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1982</YR>
<VL>126</VL>
<NO>5</NO>
<PG>855-9</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:45:07 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:45:07 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE127b"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-23 13:48:12 +0100" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;PH131b&lt;/p&gt;" NOTES_MODIFIED="2013-09-23 13:48:12 +0100" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Asher MI, Pardy RL, Coates AL, Thomas E, Macklem PT</AU>
<TI>The effects of inspiratory muscle training in patients with cystic fibrosis</TI>
<SO>Australian and New Zealand Journal of Medicine (Annual Clinical and Scientific meeting for New Zealand Fellows and Advanced Trainees)</SO>
<YR>1983</YR>
<VL>13</VL>
<PG>204</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:48:12 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:48:12 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE127a"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chatham-1997" MODIFIED="2013-09-23 13:54:20 +0100" MODIFIED_BY="[Empty name]" NAME="Chatham 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-09-23 13:54:20 +0100" MODIFIED_BY="Brian W Houston" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chatham K, Ionescu A, Davies C, Baldwin J, Enright S, Shale DJ</AU>
<TI>Through range computer generated inspiratory muscle training in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1997</YR>
<VL>24 Suppl 14</VL>
<PG>299, Abstract no: 340</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:54:20 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:54:20 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE90"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Jong-2001" MODIFIED="2013-09-23 13:55:00 +0100" MODIFIED_BY="Nikki Jahnke" NAME="de Jong 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-23 13:55:00 +0100" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;PH134&lt;br&gt;6. de Jong W, van Aalderen WM, Kraan J, Koeter GH, van der Schans CP. Inspiratory muscle training in patients with cystic fibrosis. Respiratory medicine 2001;95(1):31-36.&lt;/p&gt;" NOTES_MODIFIED="2013-09-23 13:55:00 +0100" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Jong W, van Aalderen WM, Kraan J, Koeter GH, van der Schans CP</AU>
<TI>Inspiratory muscle training in patients with cystic fibrosis</TI>
<SO>Respiratory medicine</SO>
<YR>2001</YR>
<VL>95</VL>
<NO>1</NO>
<PG>31-36</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:55:00 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:55:00 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE130"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enright-2004" MODIFIED="2013-09-23 13:56:35 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Enright 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-23 13:56:19 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enright S, Chatham K, Ionescu AA, Shale DJ, Unnithan V</AU>
<TI>A randomised double blind controlled trial of inspiratory muscle training in cystic fibrosis [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>3 Suppl</NO>
<PG>A753</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:56:19 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:56:19 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE138a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-23 13:56:35 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Enright S, Chatham K, Ionescu AA, Unnithan VB, Shale DJ</AU>
<TI>Inspiratory muscle training improves lung function and exercise capacity in adults with cystic fibrosis</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>2</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:56:35 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:56:35 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE138b"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heward-2000" MODIFIED="2013-09-23 13:58:17 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Heward 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-23 13:57:51 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell A, Enright S, Unnitham V</AU>
<TI>The effect of inspiratory muscle training on the measurement of resting energy expenditure in adult patients with cystic fibrosis and in health subjects [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 31</NO>
<PG>153S</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:57:51 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:57:51 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE146b"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-23 13:57:39 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heward C, Enright S, Chatham K, Ionescu AA, Shale DJ, Unnitham V</AU>
<TI>The effect of inspiratory muscle training on lung volumes and diaphragm structure in cystic fibrosis patients and in healthy subjects [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 31</NO>
<PG>153S</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:57:39 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:57:39 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE146a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-23 13:58:17 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Withnall L, Enright S, Chatham K, Ionescu AA, Shale DJ, Unnitham V</AU>
<TI>The effect of inspiratory muscle training on exercise capacity and inspiratory muscle function in cystic fibrosis patients and in healthy subjects [abstract]</TI>
<SO>European Repiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl31</NO>
<PG>330S</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:58:17 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:58:17 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE146c"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawyer-1993" MODIFIED="2013-09-23 13:59:10 +0100" MODIFIED_BY="[Empty name]" NAME="Sawyer 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-09-23 13:59:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sawyer EH, Clanton TL</AU>
<TI>Improved pulmonary function and exercise tolerance with inspiratory muscle conditioning in children with cystic fibrosis</TI>
<SO>Chest</SO>
<YR>1993</YR>
<VL>104</VL>
<NO>5</NO>
<PG>1490-7</PG>
<IDENTIFIERS MODIFIED="2013-09-23 13:59:10 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 13:59:10 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE170"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-10-30 11:22:18 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Howard-2000" MODIFIED="2013-09-23 14:00:16 +0100" MODIFIED_BY="[Empty name]" NAME="Howard 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-23 14:00:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howard J, Bradley J, Hewitt O, Elborn S</AU>
<TI>The active cycle of breathing (ACBT) is a more effective method of airway clearance in cystic fibrosis (CF) patients than the test of incremental respiratory endurance (TIRE) [abstract]</TI>
<SO>Pediatric Pulomonology</SO>
<YR>2000</YR>
<VL>30 Suppl 20</VL>
<PG>304, Abstract no: 457</PG>
<IDENTIFIERS MODIFIED="2013-09-23 14:00:16 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-09-23 14:00:16 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE116"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Irons-2012" MODIFIED="2013-09-24 10:18:25 +0100" MODIFIED_BY="[Empty name]" NAME="Irons 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-09-23 13:24:25 +0100" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Jung Yoon Irons [10/09/2009][][]; Claire A Glasscoe [06/10/2011][][]; Narelle Cox [03/11/2011][][]; Judy Bradley [22/02/2013][][]&lt;/p&gt;" NOTES_MODIFIED="2013-09-23 13:24:25 +0100" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>Irons JY, Kenny D, Chang AB</AU>
<TI>Let's sing out!: The effect of singing on quality of life and lung function of children and adolescents with cystic fibrosis</TI>
<SO>Www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ID=83944</SO>
<YR>2009</YR>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE185a "/>
<IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000010548"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-23 13:24:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Irons JY, Kenny DT, McElrea M, Chang AB</AU>
<TI>Singing therapy for young people with cystic fibrosis : a randomized controlled pilot study</TI>
<SO>Music and Medicine</SO>
<YR>2012</YR>
<VL>4</VL>
<NO>3</NO>
<PG>136-45</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE185b "/>
<IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000007892"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keens-1977" NAME="Keens 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keens TG, Krastins IRB, Wannamaker E, Levison H, Crozier DN, Bryan AC</AU>
<TI>Ventilatory muscle endurance training in normal subjects and patients with cystic fibrosis</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1977</YR>
<VL>116</VL>
<NO>5</NO>
<PG>853-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santana_x002d_Sosa-2013" MODIFIED="2013-09-24 10:18:16 +0100" MODIFIED_BY="Brian W Houston" NAME="Santana-Sosa 2013" YEAR="2013 May 16 [Epub ahead of print]">
<REFERENCE MODIFIED="2013-09-20 09:43:20 +0100" MODIFIED_BY="Brian W Houston" PRIMARY="NO" TYPE="OTHER">
<AU>Santana-Sosa E, Gonzalez-Saiz L, Groeneveld IF, Villa-Asensi JR, Gomez de Aguero MIB, Fleck SJ, et al</AU>
<TI>Benefits of combining inspiratory muscle with &#8216;whole muscle&#8217; training in children with cystic fibrosis: a randomised controlled trial</TI>
<SO>British Journal of Sports Medicine</SO>
<YR>2013 May 16 [Epub ahead of print]</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1136/bjsports-2012-091892"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sartori-2008" MODIFIED="2013-10-30 11:22:18 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Sartori 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-30 11:22:18 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sartori R, Barbi E, Poli F, Ronfani L, Marchetti F, Amadde O, et al</AU>
<TI>Respiratory training with a specific device in cystic fibrosis: a prospective study</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>4</NO>
<PG>313-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vivodtzev-2013" MODIFIED="2013-09-24 10:18:04 +0100" MODIFIED_BY="Brian W Houston" NAME="Vivodtzev 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-09-20 09:43:23 +0100" MODIFIED_BY="Brian W Houston" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vivodtzev I, Decorte N, Wuyam B, Gonnet N, Durieu I, Levy P, et al</AU>
<TI>Benefits of neuromuscular electrical stimulation prior to endurance training in patients with cystic fibrosis and severe pulmonary dysfunction</TI>
<SO>Chest</SO>
<YR>2013</YR>
<VL>143</VL>
<NO>2</NO>
<PG>485-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-08-09 13:39:34 +0100" MODIFIED_BY="Brian W Houston"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-09-20 09:43:23 +0100" MODIFIED_BY="Nikki Jahnke">
<ADDITIONAL_REFERENCES MODIFIED="2011-08-30 14:37:37 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Altman-1995" NAME="Altman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Absence of evidence is not evidence of absence</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>485</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bradley-2008" MODIFIED="2008-05-15 13:26:43 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Bradley 2008" TYPE="COCHRANE_REVIEW">
<AU>Bradley J, Moran F</AU>
<TI>Physical training for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-05-15 13:26:43 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2008-05-15 13:26:43 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002768.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CF-Trust-2005" NAME="CF Trust 2005" TYPE="OTHER">
<AU>Cystic Fibrosis Trust</AU>
<TI>Making a Difference: Annual Report 2005 [online]</TI>
<SO>http://www.cftrust.org.uk/scope/documentlibrary/Publications/CF-TrustAnnualReview2005.pdf</SO>
<YR>(accessed 24 August 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CF-Trust-2007" NAME="CF Trust 2007" TYPE="OTHER">
<AU>UK Cystic Fibrosis Trust</AU>
<TI>What is Cystic Fibrosis?</TI>
<SO>http://www.cftrust.org.uk/aboutcf/whatiscf/</SO>
<YR>(accessed 25th October 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chatham-2004" NAME="Chatham 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chatham K, Ionescu AA, Nixon LS, Shale DJ</AU>
<TI>A short-term comparison of two methods of sputum expectoration in cystic fibrosis</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>3</NO>
<PG>435-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002a" MODIFIED="2008-04-28 11:18:13 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Curtin 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne E</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2131-44</PG>
<IDENTIFIERS MODIFIED="2008-04-28 11:18:13 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2008-04-28 11:18:13 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/sim.1205"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002b" MODIFIED="2008-04-28 11:19:40 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Curtin 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne E</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2145-59</PG>
<IDENTIFIERS MODIFIED="2008-04-28 11:19:40 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2008-04-28 11:19:40 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/sim.1206"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002c" MODIFIED="2008-04-28 11:24:18 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Curtin 2002c" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne E</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carryover</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2161-73</PG>
<IDENTIFIERS MODIFIED="2008-04-28 11:24:18 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2008-04-28 11:24:18 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/sim.1207"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dodge-2007" NAME="Dodge 2007" TYPE="JOURNAL_ARTICLE">
<AU>Dodge JA, Lewis PA, Stanton M, Wilsher J</AU>
<TI>Cystic Fibrosis mortality and survival in the UK: 1947 -2003</TI>
<SO>European Respiratory Journal</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>3</NO>
<PG>522-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2008-04-28 11:16:07 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enright-2000" MODIFIED="2008-05-05 16:05:54 +0100" MODIFIED_BY="Brian W Houston" NAME="Enright 2000" TYPE="JOURNAL_ARTICLE">
<AU>Enright S, Chatham K, Baldwin J, Griffiths H</AU>
<TI>The effect of fixed load incremental inspiratory muscle training in the elite athlete: a pilot study</TI>
<SO>Physical Therapy in Sport</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2011-08-30 14:37:03 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Editors: Julian PT Higgins and Douglas G Altman on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group</AU>
<TI>Chapter 8:  Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2011-08-30 14:37:37 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Jonathan J Deeks, Julian PT Higgins and Douglas G Altman on behalf of the Cochrane Statistical Methods Group</AU>
<TI>Chapter 9:  Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kosorok-1996" MODIFIED="2008-05-13 14:57:41 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Kosorok 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kosorok MR, Wei WH, Farrell PM</AU>
<TI>The incidence of cystic fibrosis</TI>
<SO>Statistics in Medicine</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>5</NO>
<PG>449-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McClarey-1997" MODIFIED="2008-05-15 14:49:39 +0100" MODIFIED_BY="Nikki Jahnke" NAME="McClarey 1997" TYPE="JOURNAL_ARTICLE">
<AU>McClarey M, Duff L</AU>
<TI>Clinical effectiveness and evidence-based practice</TI>
<SO>Nursing standard: official newspaper of the Royal College of Nursing</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>52</NO>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McConnell-2002" NAME="McConnell 2002" TYPE="OTHER">
<AU>McConnell A</AU>
<TI>Clinical implications of inspiratory muscle training [online]</TI>
<SO>http://www.powerbreathe.com/pdf/inspiratory-muscle.pdf</SO>
<YR>(accessed 24 August 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2008" MODIFIED="2008-05-13 08:31:02 +0100" MODIFIED_BY="Nikki Jahnke" NAME="O'Brien 2008" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien K, Geddes L, Reid D, Brooks D, Crowe J</AU>
<TI>Inspiratory muscle training compared with other rehabilitation interventions in chronic obstructive pulmonary disease</TI>
<SO>Journal of Cardiopulmonary Rehabilitation and Prevention</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>2</NO>
<PG>128-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2005" NAME="WHO 2005" TYPE="OTHER">
<AU>World Health Organisation</AU>
<TI>Genes and human disease [online]</TI>
<SO>http://www.who.int/genomics/public/geneticdiseases/en/index.html</SO>
<YR>(accessed August 24 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-07-09 13:32:09 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Houston-2008" MODIFIED="2013-07-09 13:32:09 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Houston 2008" TYPE="COCHRANE_REVIEW">
<AU>Houston BW, van der Schans CP</AU>
<TI>Inspiratory muscle training for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-07-09 13:30:10 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-07-09 13:30:10 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD006112"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Houston-2009" MODIFIED="2013-07-09 13:31:34 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Houston 2009" TYPE="COCHRANE_REVIEW">
<AU>Houston BW, Mills N, Solis-Moya A</AU>
<TI>Inspiratory muscle training for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-07-09 13:31:34 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-07-09 13:31:34 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD006112.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-09-20 09:43:23 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-10-30 11:24:31 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-10-30 11:24:31 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-09-24 10:58:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Albinni-2004">
<CHAR_METHODS MODIFIED="2013-09-24 10:22:39 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel design over 12 weeks. <BR/>Single centre in Austria.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-24 10:58:36 +0100" MODIFIED_BY="[Empty name]">
<P>Total cohort: n = 27.</P>
<P>
<BR/>Age range: 6 - 18 years.</P>
<P>
<BR/>Gender mix: no information.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-24 10:23:06 +0100" MODIFIED_BY="[Empty name]">
<P>IMT: no details; plus, cycle ergometer training 3 times per week.</P>
<P>Control: cycle ergometer training 3 times per week.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-24 10:23:09 +0100" MODIFIED_BY="[Empty name]">
<P>FEV<SUB>1</SUB>, FVC, IMS, IME, MEC, perceived breathlessness, antibiotic use and ease or degree of expectoration.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-24 10:23:11 +0100" MODIFIED_BY="[Empty name]">
<P>IME protocol: abstract only, no details given.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-24 10:58:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amelina-2006">
<CHAR_METHODS MODIFIED="2013-09-24 10:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel design over 6 weeks.</P>
<P>Single centre in Russia.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-24 10:58:28 +0100" MODIFIED_BY="[Empty name]">
<P>Total cohort: n = 20. Treatment group: n = 10; control group: n = 10.</P>
<P>Age range was not stated, but all were adults.</P>
<P>Gender mix: no information.</P>
<P>States no significant differences between groups in terms of gender, age, weight, height, pulmonary function.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-24 10:26:27 +0100" MODIFIED_BY="[Empty name]">
<P>Threshold loading device:</P>
<P>Intervention group: 30% of PI<SUB>max</SUB>
</P>
<P>Control group: 7cm H<SUB>2</SUB>O</P>
<P>Training regimen: 10 to 15 minutes twice daily for 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-24 10:26:29 +0100" MODIFIED_BY="[Empty name]">
<P>FEV<SUB>1</SUB>, FVC, PI<SUB>max</SUB>, IC, RMS, RME and exercise capacity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-24 10:26:31 +0100" MODIFIED_BY="[Empty name]">
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-24 10:58:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asher-1983">
<CHAR_METHODS MODIFIED="2013-09-24 10:27:22 +0100" MODIFIED_BY="[Empty name]">
<P>Consecutive, self-control design over 8 weeks.</P>
<P>Trial run in Canada, unclear if single or 2 centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-24 10:58:15 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Total cohort: n = 11.</P>
<P>
<BR/>Age range: 9 - 24 years.</P>
<P>
<BR/>Gender split: no information.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-24 10:27:48 +0100" MODIFIED_BY="[Empty name]">
<P>IMT: Inspiratory resistance, 15 minutes twice daily, no dosage.</P>
<P>Control: no details provided.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-24 10:27:51 +0100" MODIFIED_BY="[Empty name]">
<P>IMS, W<SUB>max</SUB>, VO<SUB>2</SUB>max, VE and heart rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-24 10:28:02 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-24 10:58:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chatham-1997">
<CHAR_METHODS MODIFIED="2013-09-24 10:29:56 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel design over 8 weeks.</P>
<P>Trial run in UK, not clear if single centre or 2 centres.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-24 10:58:05 +0100" MODIFIED_BY="[Empty name]">
<P>Total cohort: n = 18. Treatment group: n = 9; control group: n = 9.</P>
<P>All participants were adults, but no specific age details or information on gender split given.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-24 10:31:02 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: computer-generated through range IMT (TIRE) at 80% of individual capacity.</P>
<P>Control: threshold loading device at 30% of peak; the measure used is not named.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-24 10:31:07 +0100" MODIFIED_BY="[Empty name]">
<P>Chronic Respiratory Disease Questionnaire ('mastery' and 'emotion' elements), RMS and RME.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-31 13:37:21 +0100" MODIFIED_BY="Brian W Houston"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-24 10:57:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Jong-2001">
<CHAR_METHODS MODIFIED="2013-09-24 10:31:44 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel design over 6 weeks.</P>
<P>Single centre trial in the Netherlands.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-24 10:57:57 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Total cohort: n = 16. Treatment group: n = 8; control group: n = 8.</P>
<P>Age range for total cohort 10 - 25 years. Treatment group: mean (SD) age = 17 (5.2) years; control group: mean (SD) age = 19 (5.5) years.</P>
<P>Gender split for total cohort: 8 male, 8 female. Treatment group: 4 male, 4 female; control: 4 male, 4 female.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-24 10:35:55 +0100" MODIFIED_BY="[Empty name]">
<P>IMT: threshold loading: 20 minutes a day, 5 days per week, at 40% of PI<SUB>max</SUB>.</P>
<P>Control: threshold loading: 20 minutes a day, 5 days per week. at 10% of PI<SUB>max</SUB>.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-24 10:35:59 +0100" MODIFIED_BY="[Empty name]">
<P>FEV<SUB>1</SUB>, FVC, W<SUB>max</SUB>, VO<SUB>2</SUB>max, VE<SUB>max</SUB>, IME, perceived breathlessness, general fatigue, physical fatigue, reduced activity score, reduced motivation score, mental fatigue and dyspnoea.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-24 10:36:26 +0100" MODIFIED_BY="[Empty name]">
<P>IME protocol: a commercially-available threshold-loading device (Threshold, Healthscan Products, Inc. USA) was used during an incremental loading procedure. In order to obtain pressures over 41 cm H<SUB>2</SUB>O an additional spring was inserted with a double-spring constant. Participants started inspiring from a threshold-loading device set at 30% of PI<SUB>max</SUB> for 2 min. The threshold load was then increased every 2 min in increments of 10% of Pimax. The maximal load was defined as the highest load which could be reached and maintained for at least 1 min as a percentage of PI<SUB>max</SUB>. The breathing pattern was not regulated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-24 10:59:54 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Enright-2004">
<CHAR_METHODS MODIFIED="2013-09-24 10:51:49 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel design over 8 weeks.</P>
<P>Single centre in UK.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-24 10:57:46 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Total cohort: n = 29. Treatment group 1: n = 9; treatment group 2: n = 10; control group: n = 10.<BR/>
</P>
<P>Age of total cohort (all adults): mean (SD) age = 22 (4.2) years. Treatment group 1: mean (SD) age = 24.8 (5.5) years; treatment group 2: mean (SD) age = 20 (4.7) years; control group: mean (SD) age = 21.3 (2.7) years.</P>
<P>Gender split of total cohort: 16 male, 14 female. Treatment group 1: 4 male, 6 female (according to table in paper); treatment group 2: 6 male, 4 female; control group: 6 male, 4 female.</P>
<P>All had similar age, height, weight and lung function at baseline.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-24 10:59:39 +0100" MODIFIED_BY="Brian W Houston">
<P>Intervention 1: IMT at 80% of "maximal inspiratory effort".<BR/>Intrevention 2: IMT at 20% of "maximal inspiratory effort".</P>
<P>Control: "No Training"</P>
<P>
<BR/>IMT is incremental maximal effort with progressively shorter rest periods, 3 times a week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-24 10:59:51 +0100" MODIFIED_BY="Nikki Jahnke">
<P>FEV<SUB>1</SUB>(% predicted), FVC (% predicted), PI<SUB>max</SUB>, SPI<SUB>max</SUB>, heart rate, perceived exertion, dyspnoea and Chronic Respiratory Disease Questionnaire.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-24 10:59:54 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Sample size calculation undertaken such that study needed at least 9 patients in each group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-24 11:16:24 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Heward-2000">
<CHAR_METHODS MODIFIED="2013-09-24 11:00:37 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Parallel design over 8 weeks.</P>
<P>Not clear if single or multicentre, authors from UK and USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-24 11:13:20 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Total cohort: n = 39 (19 with CF and 20 matched healthy controls). Treatment group CF: n = 9; control group CF: n = 10.</P>
<P>Age of CF adults: mean (SD) age = 22.5 (3.5) years; age of healthy adults: mean (SD) age = 21.5 (3.5) years.</P>
<P>
<BR/>Gender matched groups</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-24 11:15:18 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Treatment: IMT at 80% of "maximal effort", no dosage stated.</P>
<P>Control: no training.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-24 11:15:35 +0100" MODIFIED_BY="Nikki Jahnke">
<P>VC, TLC.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-24 11:16:24 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Only CF patients eligible in this review, 10 healthy adults in another IMT group and another control group.</P>
<P>Abstracts only available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-24 11:19:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sawyer-1993">
<CHAR_METHODS MODIFIED="2013-09-24 11:16:37 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel design over 10 weeks.</P>
<P>Single centre trial in USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-24 11:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>Total cohort: n = 20. Treatment group: n = 10; control group: n = 10.</P>
<P>Treatment group: mean (SD) age = 11.46 (2.45) years; control group: mean (SD) age = 9.76 (2.57) years.</P>
<P>No information on gender split.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-24 11:19:11 +0100" MODIFIED_BY="[Empty name]">
<P>IMT: IMT at 60% PI<SUB>max</SUB>.</P>
<P>Control: Sham IMT at 10% PI<SUB>max</SUB>.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-24 11:19:14 +0100" MODIFIED_BY="[Empty name]">
<P>FEV<SUB>1</SUB>, VC, FRC, IC, RV, TLC, RV/TLC, FEV<SUB>1</SUB>/FVC, MVV, exercise time.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>% predicted: the volume of air exhaled expressed as a percentage of the expected volume based on the physical attributes of the individual<BR/>BMI: body mass index<BR/>FEV<SUB>1</SUB>:<SUB> </SUB>volume of air exhaled over the first second of a forced exhalation<BR/>FEV<SUB>1</SUB>/FVC = the ratio of FEV<SUB>1</SUB> to FVC<BR/>FRC: functional residual capacity<BR/>FVC: total volume of air forcibly exhaled<BR/>FEF<SUB>25-75%</SUB>: forced expiratory flow 25-75%<BR/>IC: inspiratory capacity<BR/>IME: inspiratory muscle endurance<BR/>IMF: inspiratory muscle function<BR/>IMS: inspiratory muscle strength<BR/>IMT: inspiratory muscle training<BR/>MEC: maximal exercise capacity<BR/>MVV: maximum voluntary ventilation<BR/>RME: respiratory muscle endurance<BR/>RMS: respiratory muscle strength<BR/>n: number of participants<BR/>PI<SUB>max</SUB>: maximal inspiratory pressure<BR/>RV: residual volume; i.e. the volume of air retained in the lungs following a maximal, voluntary exhalation (FVC)<BR/>RV/TLC: the ratio of residual volume to total lung capacity<BR/>SD: standard deviation<BR/>SPI<SUB>max</SUB>: sustained maximal inspiratory pressure<BR/>TLC: total lung capacity; i.e. the calculated maximum potential volume of an individual's lungs<BR/>VC: the total volume of air that can be exhaled in any one breath<BR/>VE(max): peak expired ventilation<BR/>VO<SUB>2</SUB>max: peak oxygen consumption<BR/>W<SUB>max</SUB>: maximum work load</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-09-24 11:20:22 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-09-24 11:20:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Howard-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-24 11:20:09 +0100" MODIFIED_BY="Brian W Houston">
<P>Inappropriate intervention - ACBT versus TIRE not IMT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-24 11:20:11 +0100" MODIFIED_BY="Brian W Houston" STUDY_ID="STD-Irons-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-24 11:20:11 +0100" MODIFIED_BY="Brian W Houston">
<P>Inappropriate intervention - singing training and not IMT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-24 11:20:13 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Keens-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-24 11:20:13 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study excluded as allocation not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-24 11:20:15 +0100" MODIFIED_BY="Brian W Houston" STUDY_ID="STD-Santana_x002d_Sosa-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-24 11:20:15 +0100" MODIFIED_BY="Brian W Houston">
<P>Although a form of IMT was used as an intervention it was used in combination with another exercise based intervention; therefore, it was impossible to attribute any observed changes to IMT alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-24 11:20:20 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Sartori-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-24 11:20:20 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Observational study, no randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-24 11:20:22 +0100" MODIFIED_BY="Brian W Houston" STUDY_ID="STD-Vivodtzev-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-24 11:20:22 +0100" MODIFIED_BY="Brian W Houston">
<P>Inappropriate intervention - neuromuscular electrical stimulation prior to endurance training not IMT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ACBT: active cycle of breathing technique<BR/>IMT: inspiratory muscle training<BR/>TIRE: test of incremental respiratory endurance</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-08-09 13:39:34 +0100" MODIFIED_BY="Brian W Houston" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-10-30 11:18:37 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-09-24 11:19:22 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:23:14 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Albinni-2004">
<DESCRIPTION>
<P>Described as randomised, no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:26:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amelina-2006">
<DESCRIPTION>
<P>The authors only state that the allocation was random without explaining the process involved.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:28:10 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Asher-1983">
<DESCRIPTION>
<P>Described as randomised, no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:31:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chatham-1997">
<DESCRIPTION>
<P>Described as randomised, no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:00:01 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Enright-2004">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:15:44 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heward-2000">
<DESCRIPTION>
<P>Described as randomised, no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:19:22 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1993">
<DESCRIPTION>
<P>Described as randomised, no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:36:44 +0100" MODIFIED_BY="Brian W Houston" RESULT="YES" STUDY_ID="STD-de-Jong-2001">
<DESCRIPTION>
<P>Patients were assigned to 1 of 2 groups by 5 patient factors: gender; age; FEV<SUB>1</SUB>; FVC; and BMI using the minimization method.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-09-24 11:19:24 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:23:19 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Albinni-2004">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:26:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amelina-2006">
<DESCRIPTION>
<P>No details are provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:28:12 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Asher-1983">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:31:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chatham-1997">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:00:03 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Enright-2004">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:15:45 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heward-2000">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:19:24 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1993">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:36:46 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2001">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-09-24 11:19:30 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-24 10:23:25 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Albinni-2004">
<DESCRIPTION>
<P>Performance bias: clear difference between the interventions received.</P>
<P>Dectection bias: No reference to any blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-24 10:26:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amelina-2006">
<DESCRIPTION>
<P>Performance bias: The comparison group are referred to only as the "control group" with no mention of the intensity of the training used; i.e. if it was at "sham" or sub-maximal levels.</P>
<P>Dectection bias: No reference to any blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-24 10:28:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asher-1983">
<DESCRIPTION>
<P>Performance bias: no details of the control training regimen are provided = high risk.</P>
<P>Dectection bias: observer blind = low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-24 10:31:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chatham-1997">
<DESCRIPTION>
<P>Perfomance bias: the training intensities employed (80% and "threshold" 30% training) could, potentially, have led the participants to know which group they were in.</P>
<P>Dectection bias: no reference to any blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-24 11:00:13 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Enright-2004">
<DESCRIPTION>
<P>Performance bias: the comparison was "no training" making it clear to the participants which arm they were in.</P>
<P>Dectection bias: outcome assessors at the final data collection session, although they did not state whether this was the case at the initial assessment or even if the same assessors carried out all the assessments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-24 11:15:53 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Heward-2000">
<DESCRIPTION>
<P>Performance bias: the comparison was "no training" making it clear to the participants which arm they were in.</P>
<P>Detection bias: no reference to any blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-24 11:19:30 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Sawyer-1993">
<DESCRIPTION>
<P>Performance bias: there was a clear difference in the intensity of training although no attempt was made to ascertain whether the participants in the training groups knew if they received the training intensity.</P>
<P>Dectection bias: outcome assessors at the final data collection session, although they did not state whether this was the case at the initial assessment or even if the same assessors carried out all the assessments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-24 10:36:53 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-de-Jong-2001">
<DESCRIPTION>
<P>Performance bias: both training intensities were low; however, no attempt was made to ascertain whether the participants knew if the received the training intensity.</P>
<P>Detection bias: no reference to any blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-10-30 11:18:37 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-30 11:17:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albinni-2004">
<DESCRIPTION>
<P>No information provided. Intention-to-treat: unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-24 10:27:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amelina-2006">
<DESCRIPTION>
<P>No statistical data is presented for the control group.</P>
<P>1 participant from the intervention group did not complete the trial; it was not stated whether they were included or excluded from the final analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-30 11:18:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asher-1983">
<DESCRIPTION>
<P>Two participants were unable to satisfactorily perform the outcome measure PI<SUB>Max</SUB>, due to expiration up to residual volume resulting in coughing. The authors do not stipulate whether this occurred during the intervention or control phase of the trial.</P>
<P>Intention-to-treat: unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-30 11:18:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chatham-1997">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion; no statistical data is presented for the control group.</P>
<P>Intention-to-treat: 3 from 18 (17%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-30 11:18:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Enright-2004">
<DESCRIPTION>
<P>No mention is made of whether all participants completed the trial or not. Nor are there any statistical indications.</P>
<P>Intention-to-treat: unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-30 11:18:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heward-2000">
<DESCRIPTION>
<P>No information provided.</P>
<P>Intention-to-treat: unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-30 11:18:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sawyer-1993">
<DESCRIPTION>
<P>2 participants removed from analysis and the reasons for this were explained; however, it is unclear which group(s) they were in.<BR/>Intention-to-treat: unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-30 11:18:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-de-Jong-2001">
<DESCRIPTION>
<P>1 participant in the intervention group was withdrawn due to earache experienced whilst training at 40% of PI<SUB>max</SUB>.</P>
<P>Intention-to-treat: 1 from 15 (6%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-09-24 11:19:38 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:23:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albinni-2004">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amelina-2006">
<DESCRIPTION>
<P>2 outcomes (respiratory muscle strength and dyspnoea) are mentioned as having been analysed, but no data are provided for them.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:28:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asher-1983">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-20 15:14:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chatham-1997">
<DESCRIPTION>
<P>As this study (to date) is only published in abstract form it is unclear whether the reported outcomes are all that were analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:00:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Enright-2004">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:16:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heward-2000">
<DESCRIPTION>
<P>The post-training pulmonary function results were not presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:19:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1993">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:37:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2001">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-09-24 11:19:40 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:23:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albinni-2004">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:27:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amelina-2006">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:28:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asher-1983">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:31:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chatham-1997">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:00:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Enright-2004">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:16:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heward-2000">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 11:19:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1993">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-24 10:37:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2001">
<DESCRIPTION>
<P>Insufficient information available to arrive at a conclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2013-10-30 11:20:49 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-10-30 11:20:49 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Explanation of terms</TITLE>
<TABLE COLS="2" ROWS="13">
<TR>
<TH>
<P>Term</P>
</TH>
<TH>
<P>Explanation</P>
</TH>
</TR>
<TR>
<TD>
<P>Continuous training</P>
</TD>
<TD>
<P>Training at 70% to 80% of maximum effort for 30 to 45 minutes. The percentage of maximal effort or the duration of the training (or both) may be adjusted depending on the goal of the training.</P>
</TD>
</TR>
<TR>
<TD>
<P>Elastic load</P>
</TD>
<TD>
<P>Refers to the load imposed by the stiffness of the lung and chest wall that must be overcome by the inspiratory muscles in order to generate inspiratory flow. Elastic loads are greater when breathing from a higher lung volume as a consequence of the associated decrease in lung and chest wall compliance. Imposing elastic loads has not been used to train the inspiratory muscles most likely due to the need for complicated equipment and poor clinical utility.</P>
</TD>
</TR>
<TR>
<TD>
<P>Forced expiratory volume at 1 second (FEV<SUB>1</SUB>)</P>
</TD>
<TD>
<P>The volume of air expelled during the 1st second of forced exhalation from total lung capacity.</P>
</TD>
</TR>
<TR>
<TD>
<P>Forced vital capacity (FVC)</P>
</TD>
<TD>
<P>The total volume of air expelled during a forced exhalation from total lung capacity.</P>
</TD>
</TR>
<TR>
<TD>
<P>Inspiratory capacity (IC)</P>
</TD>
<TD>
<P>The maximum volume of air taken into the lungs during a maximal inhalation from functional residual capacity.</P>
</TD>
</TR>
<TR>
<TD>
<P>Forced expiratory flow 25-75% (FEF<SUB>25-75%</SUB>)</P>
</TD>
<TD>
<P>The speed of the air leaving the lungs during the middle section of a forced exhalation.</P>
</TD>
</TR>
<TR>
<TD>
<P>Interval training</P>
</TD>
<TD>
<P>Periods of intense training interspersed with periods of recuperation; as with continuous training, the level of effort required during the training period may be adjusted to suit the individual and the intended goal. The period of recuperation will be adjusted accordingly.</P>
</TD>
</TR>
<TR>
<TD>
<P>Maximal inspiratory pressure (PI<SUB>max</SUB>)</P>
</TD>
<TD>
<P>The maximum pressure generated by the inspiratory muscles against an occluded airway.</P>
</TD>
</TR>
<TR>
<TD>
<P>Resistive loading</P>
</TD>
<TD>
<P>Requires person to breathe through a narrow inspiratory pathway or aperture. The load imposed is dependent on inspiratory flow, i.e. when using resistive training devices, participants can reduce the load imposed by manipulating their breathing pattern. Breathing pattern, specifically inspiratory flow, should be controlled when using resistive inspiratory muscle training devices.</P>
</TD>
</TR>
<TR>
<TD>
<P>Threshold loading</P>
</TD>
<TD>
<P>Requires the person to inspire through a device which imposes a threshold load via either a weighted plunger system or a spring-loaded valve. The person needs to generate a critical inspiratory pressure, prior to the threshold valve opening and allowing inspiratory flow. Once the threshold valve is open, pressure and flow are largely independent and therefore the person is unable to reduce the load imposed by the device by manipulations in breathing pattern.</P>
</TD>
</TR>
<TR>
<TD>
<P>Total lung capacity (TLC)</P>
</TD>
<TD>
<P>The maximum amount of air the lungs can hold when they are fully inflated.</P>
</TD>
</TR>
<TR>
<TD>
<P>Voluntary isocapnic (normocapnic) hyperpnoea</P>
</TD>
<TD>
<P>Requires the person to maintain a high level of minute ventilation for a specified period. Imposes a high flow, low pressure load on the inspiratory muscles which is analogous to the loads borne by the inspiratory muscles during periods of increased minute ventilation (i.e. during exercise). Requires the use of complex equipment to ensure stable levels of carbon dioxide in the arterial blood (PaCO2), so is rarely used in the clinical setting.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-08-31 15:51:29 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-08-31 15:44:50 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>IMT (80% of maximal effort) versus control</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2011-08-31 13:56:11 +0100" MODIFIED_BY="Brian W Houston" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Forced expiratory volume at one second (litres)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.01" MODIFIED="2011-08-31 13:56:11 +0100" MODIFIED_BY="Brian W Houston" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Two to six months</NAME>
<CONT_DATA CI_END="0.9005413038413704" CI_START="-0.9005413038413704" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2008-05-05 13:33:16 +0100" MODIFIED_BY="Brian W Houston" ORDER="41" SD_1="1.0" SD_2="1.0" SE="0.45946829173634074" STUDY_ID="STD-Enright-2004" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-08-31 15:44:50 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.3" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Forced vital capacity (litres)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2011-08-31 15:44:50 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Two to six months</NAME>
<CONT_DATA CI_END="1.0993894603108805" CI_START="-0.8993894603108804" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="2.9" ORDER="2" SD_1="1.2" SD_2="1.0" SE="0.5099019513592785" STUDY_ID="STD-Enright-2004" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2011-08-31 14:00:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.145163094046708" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Chronic Respiratory Disease Questionnaire (mastery)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMT (80% max)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.10626639232180723" CI_START="-6.106266392321807" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="22.1" MEAN_2="25.1" MODIFIED="2011-08-26 11:02:09 +0100" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="3.1" SD_2="3.8" SE="1.5848589141553824" STUDY_ID="STD-Enright-2004" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2011-08-31 14:00:34 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="17.138267596823667" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Chronic Respiratory Disease Questionnaire (emotion)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMT (80% max)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2519813122977732" CI_START="-11.251981312297772" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="32.4" MEAN_2="37.4" MODIFIED="2011-08-26 11:01:07 +0100" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="8.2" SD_2="5.2" SE="3.189844997975781" STUDY_ID="STD-Enright-2004" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-08-31 15:45:44 +0100" MODIFIED_BY="Nikki Jahnke" NO="2">
<NAME>IMT (60% of maximal effort) versus control</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2011-08-31 15:45:04 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Forced expiratory volume at one second (litres)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" MODIFIED="2011-08-31 15:45:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Two to six months</NAME>
<CONT_DATA CI_END="1.2464846612109253" CI_START="-0.14648466121092507" EFFECT_SIZE="0.55" ESTIMABLE="YES" MEAN_1="1.96" MEAN_2="1.41" MODIFIED="2008-05-01 16:14:34 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="0.86" SD_2="0.63" SE="0.3553558466914225" STUDY_ID="STD-Sawyer-1993" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2011-08-31 15:45:44 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="58.432030295853515" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>PImax (cmH2O)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" MODIFIED="2011-08-31 15:45:40 +0100" MODIFIED_BY="Brian W Houston" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Two to six months</NAME>
<CONT_DATA CI_END="43.36532514594785" CI_START="8.634674854052147" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="121.0" MEAN_2="95.0" ORDER="40" SD_1="23.0" SD_2="16.0" SE="8.860022573334675" STUDY_ID="STD-Sawyer-1993" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-08-31 15:46:23 +0100" MODIFIED_BY="Nikki Jahnke" NO="3">
<NAME>IMT (40% of maximal effort) versus control</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2011-08-31 15:45:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.6409624956315825" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Forced expiratory volume at one second (litres)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Less than two months</NAME>
<CONT_DATA CI_END="0.6904045665800808" CI_START="-1.1504045665800806" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.56" ORDER="3" SD_1="0.71" SD_2="1.09" SE="0.46960279568406077" STUDY_ID="STD-de-Jong-2001" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2011-08-31 15:46:04 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="48.4993433058706" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Forced expiratory volume at one second (% predicted)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Less than two months</NAME>
<CONT_DATA CI_END="22.413485873236674" CI_START="-28.413485873236674" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="73.0" ORDER="4" SD_1="21.0" SD_2="29.0" SE="12.96630247988994" STUDY_ID="STD-de-Jong-2001" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2011-08-31 15:46:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.724066078802442" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Forced vital capacity (litres)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Less than two months</NAME>
<CONT_DATA CI_END="0.6769504985574312" CI_START="-1.1969504985574315" EFFECT_SIZE="-0.26000000000000023" ESTIMABLE="YES" MEAN_1="3.07" MEAN_2="3.33" ORDER="5" SD_1="0.9" SD_2="0.95" SE="0.478044752836265" STUDY_ID="STD-de-Jong-2001" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2011-08-31 15:46:16 +0100" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="26.12264425643743" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Forced vital capacity (% predicted)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>Less than two months</NAME>
<CONT_DATA CI_END="19.489425836726493" CI_START="-21.489425836726493" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="80.0" ORDER="6" SD_1="18.0" SD_2="21.0" SE="10.453980786557544" STUDY_ID="STD-de-Jong-2001" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2011-08-31 15:46:23 +0100" MODIFIED_BY="Nikki Jahnke" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="46.48" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Inspiratory muscle endurance (%PImax)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Less than two months</NAME>
<CONT_DATA CI_END="23.449444626539186" CI_START="0.5505553734608135" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="66.0" MEAN_2="54.0" ORDER="7" SD_1="14.0" SD_2="7.0" SE="5.841660722773962" STUDY_ID="STD-de-Jong-2001" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-08-31 15:51:29 +0100" MODIFIED_BY="Brian W Houston" NO="4">
<NAME>IMT (20% of maximal effort) versus control</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2011-08-31 15:50:39 +0100" MODIFIED_BY="Brian W Houston" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Forced expiratory volume at one second (litres)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.01" MODIFIED="2011-08-31 15:50:39 +0100" MODIFIED_BY="Brian W Houston" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Two to six months</NAME>
<CONT_DATA CI_END="1.7213915559486106" CI_START="-0.12139155594861095" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="2.0" MODIFIED="2008-05-05 13:34:10 +0100" MODIFIED_BY="Brian W Houston" ORDER="42" SD_1="1.1" SD_2="1.0" SE="0.47010637094172636" STUDY_ID="STD-Enright-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2011-08-31 15:50:34 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.182144165314423" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Forced expiratory volume at one second (% predicted)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.01" MODIFIED="2011-08-31 15:50:34 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Two to six months</NAME>
<CONT_DATA CI_END="1.7213915559486106" CI_START="-0.12139155594861095" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="2.0" ORDER="8" SD_1="1.1" SD_2="1.0" SE="0.47010637094172636" STUDY_ID="STD-Enright-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2011-08-31 15:50:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.290128827303924" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Forced vital capacity (litres)</NAME>
<GROUP_LABEL_1>IMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.03.01" MODIFIED="2011-08-31 15:50:31 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Two to six months</NAME>
<CONT_DATA CI_END="1.8681507900370513" CI_START="-0.06815079003705149" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="2.9" MODIFIED="2008-05-13 08:07:23 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="9" SD_1="1.2" SD_2="1.0" SE="0.4939635614091388" STUDY_ID="STD-Enright-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-10-30 11:11:14 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-10-30 11:11:14 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-10-30 11:11:14 +0000" MODIFIED_BY="Nikki Jahnke">Search strategy: MEDLINE, Embase, CINAHL, AMED, BIOSIS, EMB reviews (OVID-WEB)</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-10 12:05:15 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="5">
<TR>
<TD>
<P>Date of Search</P>
</TD>
<TD>
<P>01/08/2013</P>
</TD>
</TR>
<TR>
<TD>
<P>Years Covered</P>
</TD>
<TD>
<P>1966 to present</P>
</TD>
</TR>
<TR>
<TD>
<P>Complete Strategy</P>
</TD>
<TD>
<P>1. randomised controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomised controlled trials.sh.<BR/>4. random allocation.sh.<BR/>5. double blind method.sh.<BR/>6. single blind method.sh.<BR/>7. or/1-6<BR/>8. (animals not human).sh.<BR/>9. 7 not 8<BR/>10. clinical trial.pt.<BR/>11. exp clinical trials/<BR/>12. (clin$ adj25 trial$).ti,ab.<BR/>13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>14. placebos.sh.<BR/>15. placebo$.ti,ab.<BR/>16. random$.ti,ab.<BR/>17. research design.sh.<BR/>18. or/10-17<BR/>19. 18 not 8<BR/>20. 19 not 9<BR/>21. comparative study.sh.<BR/>22. exp evaluation studies/<BR/>23. follow up studies.sh.<BR/>24. prospective studies.sh.<BR/>25. (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>26. or/21-25<BR/>27. 26 not 8<BR/>28. 27 not (9 or 20)<BR/>29. 9 or 20 or 28<BR/>30. exp cystic fibrosis/<BR/>31. cystic fibrosis.mp.<BR/>32. (fibrocystic adj3 disease adj3 pancreas).tw.<BR/>33. mucoviscidos$.mp.<BR/>34. (cystic$ adj10 fibros$).tw.<BR/>35. (pancreatic adj3 cystic adj3 fibrosis).mp.<BR/>36. or/30-35<BR/>37. 29 and 36<BR/>38. ((train$ or cond$) adj25 (inspirator$ or ventilator$ or respirator$ or pulmonar$)).mp.<BR/>39. (voluntar$ adj3 isocapn$ adj3 hyperpnoe$).tw.<BR/>40. (resist$ adj3 load$).tw.<BR/>41. (pressu$ adj3 thresh$ adj3 load$).tw.<BR/>42. (elas$ adj3 load$).tw.<BR/>43. (incre$ adj3 thresh$ adj3 load$).tw.<BR/>44. or/38-43<BR/>45. 44 not 8<BR/>46. 45 and 37<BR/>47. remove duplicates from 46</P>
</TD>
</TR>
<TR>
<TD>
<P>Summary of Strategy</P>
</TD>
<TD>
<P>Lines 1 &amp; 29 are the Cochrane RCT filter.<BR/>Lines 30 to 37 are the Cochrane cystic fibrosis filter.<BR/>Lines 38 to 45 were to isolate the intervention of interest.<BR/>The remainder were to combine these three themes.</P>
</TD>
</TR>
<TR>
<TD>
<P>Language Restrictions</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-10-10 12:05:07 +0100" MODIFIED_BY="Nikki Jahnke" NO="2">
<TITLE MODIFIED="2008-04-28 10:36:08 +0100" MODIFIED_BY="Nikki Jahnke">Search strategy: PEDro</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-10 12:05:07 +0100" MODIFIED_BY="Nikki Jahnke">
<TABLE COLS="2" ROWS="5">
<TR>
<TD>
<P>Date of search</P>
</TD>
<TD>
<P>01/08/2013</P>
</TD>
</TR>
<TR>
<TD>
<P>Years covered</P>
</TD>
<TD>
<P>1929 to present</P>
</TD>
</TR>
<TR>
<TD>
<P>Complete strategy</P>
</TD>
<TD>
<P>1. inspir* mus* train*<BR/>2. resp* mus* train*<BR/>3. resp* mus* cond*<BR/>4. resist* load*<BR/>5. press* thresh* load*<BR/>6. incre* thresh* load*<BR/>7. cystic fibrosis<BR/>8. cyst* fibro*<BR/>9. pancreatic cystic fibrosis<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Summary of strategy</P>
</TD>
<TD>
<P>PEDro is a database of controlled clinical trials, therefore no specific design oriented search terms.<BR/>All terms were geared to isolate the condition and the intervention.<BR/>The returned citations were then manually combined to be specific to the review question.</P>
</TD>
</TR>
<TR>
<TD>
<P>Language restrictions</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-10-10 12:05:18 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-04-28 10:38:43 +0100" MODIFIED_BY="Nikki Jahnke">Search strategy: Science Direct</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-10 12:05:18 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="5">
<TR>
<TD>
<P>Date of search</P>
</TD>
<TD>
<P>01/08/2013</P>
</TD>
</TR>
<TR>
<TD>
<P>Years covered</P>
</TD>
<TD>
<P>1823 to present</P>
</TD>
</TR>
<TR>
<TD>
<P>Complete strategy</P>
</TD>
<TD>
<P>1: (Title-Abstr-Key (random*)) OR (Title-Abstr-Key (placebo*)) OR (Title-Abstr-Key ((singl* or doubl* or trebl* or tripl*) w/25 (blind* or mask*))) OR (Title-Abstr-Key (clin* w/25 trial*))<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>2: ((Title-Abstr-Key (random*)) OR (Title-Abstr-Key (placebo*)) OR (Title-Abstr-Key ((singl* or doubl* or trebl* or tripl*) w/25 (blind* or mask*))) OR (Title-Abstr-Key (clin* w/25 trial*))) OR ((Title-Abstr-Key (single blind method)) OR (Title-Abstr-Key (double blind method)) OR (Title-Abstr-Key (random allocation)) OR (Title-Abstr-Key (controlled clinical trial)) OR (Title-Abstr-Key (randomised controlled trial)))<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>3: Title-Abstr-Key (cystic fibrosis)<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>4: Title-Abstr-Key (fibrocystic w/3 disease w/3 pancreas)<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>5: Title-Abstr-Key (mucoviscidos*)<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>6: Title-Abstr-Key (cystic* w/10 fibros*)<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>7: Title-Abstr-Key (pancreatic w/3 cystic w/3 fibrosis)<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>8: (Title-Abstr-Key (pancreatic w/3 cystic w/3 fibrosis)) OR (Title-Abstr-Key (cystic* w/10 fibros*)) OR (Title-Abstr-Key (mucoviscidos*)) OR (Title-Abstr-Key (fibrocystic w/3 disease w/3 pancreas)) OR (Title-Abstr-Key (cystic fibrosis))<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>9: Title-Abstr-Key (train* or cond*) w/3 (inspirator* or ventilator* or respirator* or pulmonar*)<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>10: Title-Abstr-Key (resist* w/3 load*)<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>11: Title-Abstr-Key (inspiratory muscle training)<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>12: (Title-Abstr-Key (inspiratory muscle training)) OR (Title-Abstr-Key (resist* w/3 load*)) OR (Title-Abstr-Key (train* or cond*) w/3 (inspirator* or ventilator* or respirator* or pulmonar*))<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>13: (Title-Abstr-Key (inspiratory muscle training)) OR (Title-Abstr-Key (resist* w/3 load*)) OR (Title-Abstr-Key (train* or cond*) w/3 (inspirator* or ventilator* or respirator* or pulmonar*))<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>14: ((Title-Abstr-Key (inspiratory muscle training)) OR (Title-Abstr-Key (resist* w/3 load*)) OR (Title-Abstr-Key (train* or cond*) w/3 (inspirator* or ventilator* or respirator* or pulmonar*))) AND ((Title-Abstr-Key (pancreatic w/3 cystic w/3 fibrosis)) OR (Title-Abstr-Key (cystic* w/10 fibros*)) OR (Title-Abstr-Key (mucoviscidos*)) OR (Title-Abstr-Key (fibrocystic w/3 disease w/3 pancreas)) OR (Title-Abstr-Key (cystic fibrosis))) AND (((Title-Abstr-Key (random*)) OR (Title-Abstr-Key (placebo*)) OR (Title-Abstr-Key ((singl* or doubl* or trebl* or tripl*) w/25 (blind* or mask*))) OR (Title-Abstr-Key (clin* w/25 trial*))) OR ((Title-Abstr-Key (single blind method)) OR (Title-Abstr-Key (double blind method)) OR (Title-Abstr-Key (random allocation)) OR (Title-Abstr-Key (controlled clinical trial)) OR (Title-Abstr-Key (randomised controlled trial))))<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>15: ((Title-Abstr-Key (pancreatic w/3 cystic w/3 fibrosis)) OR (Title-Abstr-Key (cystic* w/10 fibros*)) OR (Title-Abstr-Key (mucoviscidos*)) OR (Title-Abstr-Key (fibrocystic w/3 disease w/3 pancreas)) OR (Title-Abstr-Key (cystic fibrosis))) AND (((Title-Abstr-Key (random*)) OR (Title-Abstr-Key (placebo*)) OR (Title-Abstr-Key ((singl* or doubl* or trebl* or tripl*) w/25 (blind* or mask*))) OR (Title-Abstr-Key (clin* w/25 trial*))) OR ((Title-Abstr-Key (single blind method)) OR (Title-Abstr-Key (double blind method)) OR (Title-Abstr-Key (random allocation)) OR (Title-Abstr-Key (controlled clinical trial)) OR (Title-Abstr-Key (randomised controlled trial))))<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>16: ((Title-Abstr-Key (inspiratory muscle training)) OR (Title-Abstr-Key (resist* w/3 load*)) OR (Title-Abstr-Key (train* or cond*) w/3 (inspirator* or ventilator* or respirator* or pulmonar*))) AND ((Title-Abstr-Key (pancreatic w/3 cystic w/3 fibrosis)) OR (Title-Abstr-Key (cystic* w/10 fibros*)) OR (Title-Abstr-Key (mucoviscidos*)) OR (Title-Abstr-Key (fibrocystic w/3 disease w/3 pancreas)) OR (Title-Abstr-Key (cystic fibrosis)))<BR/>[All Sources(Medicine and Dentistry,Nursing and Health Professions)]<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Summary of strategy</P>
</TD>
<TD>
<P>Lines 1 &amp; 2 were to isolate studies of appropriate design.<BR/>Lines 3 to 8 were to isolate the condition of interest.<BR/>Lines 9 to 13 were to isolate the intervention of interest.<BR/>The remainder were to combine these three themes.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Language restrictions</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-10-10 12:05:28 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-04-28 10:39:09 +0100" MODIFIED_BY="Nikki Jahnke">Search strategy: SCOPUS</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-10 12:05:28 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="5">
<TR>
<TD>
<P>Date of search</P>
</TD>
<TD>
<P>01/08/2013</P>
</TD>
</TR>
<TR>
<TD>
<P>Years covered</P>
</TD>
<TD>
<P>1966 to present</P>
</TD>
</TR>
<TR>
<TD>
<P>Complete strategy</P>
</TD>
<TD>
<P>1: TITLE-ABS-KEY(randomised controlled trial)<BR/>2: TITLE-ABS-KEY(controlled clinical trial)<BR/>3: TITLE-ABS-KEY(random allocation)<BR/>4: TITLE-ABS-KEY(double blind method)<BR/>5: TITLE-ABS-KEY(single blind method)<BR/>6: TITLE-ABS-KEY(clin* W/25 trial*)<BR/>7: ((TITLE-ABS-KEY(randomised controlled trial)) OR (TITLE-ABS-KEY(controlled clinical trial)) OR (TITLE-ABS-KEY(random allocation)) OR (TITLE-ABS-KEY(double blind method)) OR (TITLE-ABS-KEY(single blind method))) OR (TITLE-ABS-KEY(clin* W/25 trial*))<BR/>8: INDEXTERMS(cystic fibrosis)<BR/>9: TITLE-ABS-KEY(fibrocystic W/3 disease W/3 pancreas)<BR/>10: TITLE-ABS-KEY(mucoviscidos*)<BR/>11: TITLE-ABS-KEY(cystic* W/10 fibros*)<BR/>12: TITLE-ABS-KEY(pancreatic W/3 cystic W/3 fibrosis)<BR/>13: (INDEXTERMS(cystic fibrosis)) OR (TITLE-ABS-KEY(fibrocystic W/3 disease W/3 pancreas)) OR (TITLE-ABS-KEY(mucoviscidos*)) OR (TITLE-ABS-KEY(cystic* W/10 fibros*)) OR (TITLE-ABS-KEY(pancreatic W/3 cystic W/3 fibrosis))<BR/>14: TITLE-ABS-KEY(respiratory muscle training)<BR/>15: TITLE-ABS-KEY(ventilatory muscle training)<BR/>16: TITLE-ABS-KEY(pulmonary muscle training)<BR/>17: TITLE-ABS-KEY(resist* W/3 load*)<BR/>18: TITLE-ABS-KEY(pressu* W/3 thresh* W/3 load*)<BR/>19: TITLE-ABS-KEY(elas* W/3 load*)<BR/>20: TITLE-ABS-KEY(incre* W/3 thresh* W/3 load*)<BR/>21: (TITLE-ABS-KEY(pressu* W/3 thresh* W/3 load*)) OR (TITLE-ABS-KEY(elas* W/3 load*)) OR (TITLE-ABS-KEY(incre* W/3 thresh* W/3 load*)) OR ((TITLE-ABS-KEY(inspiratory muscle training)) OR (TITLE-ABS-KEY(respiratory muscle training)) OR (TITLE-ABS-KEY(ventilatory muscle training)) OR (TITLE-ABS-KEY(pulmonary muscle training)) OR (TITLE-ABS-KEY(resist* W/3 load*)))<BR/>22: ((INDEXTERMS(cystic fibrosis)) OR (TITLE-ABS-KEY(fibrocystic W/3 disease W/3 pancreas)) OR (TITLE-ABS-KEY(mucoviscidos*)) OR (TITLE-ABS-KEY(cystic* W/10 fibros*)) OR (TITLE-ABS-KEY(pancreatic W/3 cystic W/3 fibrosis))) AND (((TITLE-ABS-KEY(randomised controlled trial)) OR (TITLE-ABS-KEY(controlled clinical trial)) OR (TITLE-ABS-KEY(random allocation)) OR (TITLE-ABS-KEY(double blind method)) OR (TITLE-ABS-KEY(single blind method))) OR (TITLE-ABS-KEY(clin* W/25 trial*))) AND ((TITLE-ABS-KEY(pressu* W/3 thresh* W/3 load*)) OR (TITLE-ABS-KEY(elas* W/3 load*)) OR (TITLE-ABS-KEY(incre* W/3 thresh* W/3 load*)) OR ((TITLE-ABS-KEY(inspiratory muscle traning)) OR (TITLE-ABS-KEY(respiratory muscle training)) OR (TITLE-ABS-KEY(ventilatory muscle training)) OR (TITLE-ABS-KEY(pulmonary muscle training)) OR (TITLE-ABS-KEY(resist* W/3 load*))))<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Summary of strategy</P>
</TD>
<TD>
<P>Lines 1 to 7 were to isolate appropriate study design.<BR/>Lines 8 to 13 were to isolate the condition.<BR/>Lines 14 to 21 were to isolate the intervention.<BR/>Line 22: Combines these three themes.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Language restrictions</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-10-10 12:05:39 +0100" MODIFIED_BY="Nikki Jahnke" NO="5">
<TITLE MODIFIED="2011-08-31 16:12:00 +0100" MODIFIED_BY="Nikki Jahnke">Search strategy: MEDLINE, CINHAL and AMED (EBSCOHost)</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-10 12:05:39 +0100" MODIFIED_BY="Nikki Jahnke">
<TABLE COLS="2" ROWS="5">
<TR>
<TD>
<P>Date of search</P>
</TD>
<TD>
<P>01/08/2013</P>
</TD>
</TR>
<TR>
<TD>
<P>Years covered</P>
</TD>
<TD>
<P>1966 to present</P>
</TD>
</TR>
<TR>
<TD>
<P>Complete strategy</P>
</TD>
<TD>
<P>1: TITLE-ABS-KEY(randomised controlled trial)<BR/>2: TITLE-ABS-KEY(controlled clinical trial)<BR/>3: TITLE-ABS-KEY(random allocation)<BR/>4: TITLE-ABS-KEY(double blind method)<BR/>5: TITLE-ABS-KEY(single blind method)<BR/>6: TITLE-ABS-KEY(clin* W/25 trial*)<BR/>7: ((TITLE-ABS-KEY(randomised controlled trial)) OR (TITLE-ABS-KEY(controlled clinical trial)) OR (TITLE-ABS-KEY(random allocation)) OR (TITLE-ABS-KEY(double blind method)) OR (TITLE-ABS-KEY(single blind method))) OR (TITLE-ABS-KEY(clin* W/25 trial*))<BR/>8: INDEXTERMS(cystic fibrosis)<BR/>9: TITLE-ABS-KEY(fibrocystic W/3 disease W/3 pancreas)<BR/>10: TITLE-ABS-KEY(mucoviscidos*)<BR/>11: TITLE-ABS-KEY(cystic* W/10 fibros*)<BR/>12: TITLE-ABS-KEY(pancreatic W/3 cystic W/3 fibrosis)<BR/>13: (INDEXTERMS(cystic fibrosis)) OR (TITLE-ABS-KEY(fibrocystic W/3 disease W/3 pancreas)) OR (TITLE-ABS-KEY(mucoviscidos*)) OR (TITLE-ABS-KEY(cystic* W/10 fibros*)) OR (TITLE-ABS-KEY(pancreatic W/3 cystic W/3 fibrosis))<BR/>14: TITLE-ABS-KEY(respiratory muscle training)<BR/>15: TITLE-ABS-KEY(ventilatory muscle training)<BR/>16: TITLE-ABS-KEY(pulmonary muscle training)<BR/>17: TITLE-ABS-KEY(resist* W/3 load*)<BR/>18: TITLE-ABS-KEY(pressu* W/3 thresh* W/3 load*)<BR/>19: TITLE-ABS-KEY(elas* W/3 load*)<BR/>20: TITLE-ABS-KEY(incre* W/3 thresh* W/3 load*)<BR/>21: (TITLE-ABS-KEY(pressu* W/3 thresh* W/3 load*)) OR (TITLE-ABS-KEY(elas* W/3 load*)) OR (TITLE-ABS-KEY(incre* W/3 thresh* W/3 load*)) OR ((TITLE-ABS-KEY(inspiratory muscle training)) OR (TITLE-ABS-KEY(respiratory muscle training)) OR (TITLE-ABS-KEY(ventilatory muscle training)) OR (TITLE-ABS-KEY(pulmonary muscle training)) OR (TITLE-ABS-KEY(resist* W/3 load*)))<BR/>22: ((INDEXTERMS(cystic fibrosis)) OR (TITLE-ABS-KEY(fibrocystic W/3 disease W/3 pancreas)) OR (TITLE-ABS-KEY(mucoviscidos*)) OR (TITLE-ABS-KEY(cystic* W/10 fibros*)) OR (TITLE-ABS-KEY(pancreatic W/3 cystic W/3 fibrosis))) AND (((TITLE-ABS-KEY(randomised controlled trial)) OR (TITLE-ABS-KEY(controlled clinical trial)) OR (TITLE-ABS-KEY(random allocation)) OR (TITLE-ABS-KEY(double blind method)) OR (TITLE-ABS-KEY(single blind method))) OR (TITLE-ABS-KEY(clin* W/25 trial*))) AND ((TITLE-ABS-KEY(pressu* W/3 thresh* W/3 load*)) OR (TITLE-ABS-KEY(elas* W/3 load*)) OR (TITLE-ABS-KEY(incre* W/3 thresh* W/3 load*)) OR ((TITLE-ABS-KEY(inspiratory muscle traning)) OR (TITLE-ABS-KEY(respiratory muscle training)) OR (TITLE-ABS-KEY(ventilatory muscle training)) OR (TITLE-ABS-KEY(pulmonary muscle training)) OR (TITLE-ABS-KEY(resist* W/3 load*))))<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Summary of strategy</P>
</TD>
<TD>
<P>Lines 1 to 7 were to isolate appropriate study design.<BR/>Lines 8 to 13 were to isolate the condition.<BR/>Lines 14 to 21 were to isolate the intervention.<BR/>Line 22: Combines these three themes.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Language restrictions</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>